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SUMMARY
P r o s p e c t i v e  e p i d e m i o l o g i c a l  studies show that 
raised plasma cholesterol is a major risk factor for the 
d e v e l o p m e n t  of ischaemic heart disease. Recent evidence 
indicates that reducing plasma cholesterol c o n c e n t r a t i o n  
reduces risk from the disease.
Cholesterol is transported in the plasma mainly 
by low den s i t y  l i p o p r o t e i n s  (LDL) and these p a r t i c l e s  
also confer risk if present in high concentrations.
It is important to determine the m e c h a n i s m s  by 
w h i c h  LDL is r emoved from the plasma and catabolised by 
the tissues of the body. The arterial wall is especially 
i m p o r t a n t  in this respect as it can accumulate excessive 
quantities of cholesterol.
LDL catabolism is divided into two pathways:
1) L D L - r e c e p t o r - d e p e n d e n t  c a t a b o l i s m  is now a well 
understood p r o c e s s  by which a r e c e p t o r  r e c o g n i s e s  
apol ipoprote in B (the sole apol ipoprotein m o i e t y  on 
LDL) and m e d i a t e s  the i n t e r n a l i s a t i o n  of the lipo­
protein. It is then t r a n s p o r t e d  to the lysosome, 
d e g r a d e d  and the cholesterol relea s e d  for cellular 
needs. The p a t h w a y  is a u t o r e g u l a t e d  by c e l l u l a r  
r e q u i r e m e n t s  for the sterol. In most animals, 
including man, a p p r o x i m a t e l y  one half of LDL 
catabolism occurs by this route.
XXI .
2) L D L - r e c e p t o r - i n d e p e n d e n t  c a t a b o l i s m  is less well 
defined. Studies have indicated that the r e t i c u l o ­
e n d o t h e l i a l  system plays a role in this s c a v e n g e r  
path w a y .
The purpose of the present study is to increase 
u n d e r s tanding of the role played by the r e t i c u l o e n d o ­
t h e l i a l  system (RE system) in LDL metabolism. However, 
because the RE system is a disseminated tissue it is not 
as easy to study as, for example, the liver w h i c h  can 
even be removed from the animal intact.
One approach to this problem is functionally to 
block the cells of the system by injection of m a t e r i a l  
w h i c h  will be p h a g o c y t o c e d  by these macrophages. This 
w a s  a c h i e v e d  using three agents; a) ethyl ol e a t e  
e m u l s i o n ,  b) muramyl tripeptide i n c o r p o r a t e d  into 
triolein emulsion and c) muramyl dipeptide conjugated to 
a c e t y l a t e d  bovine serum albumin (for which the cells of 
the RE system have a receptor). The end r esult was the 
same regardless of the agent employed;
The following s u m m arises the e s s e n t i a l  
conclusions of the thesis.
1) The RE system is important in lipoprotein catabolism. 
Blockage of the system causes an increase in p l a s m a  
t r i g l y c e r i d e  and cholesterol levels. The r aised 
total cholesterol is almost entirely accounted for by 
an increase in LDL cholesterol.
xxii :
2) RE cells are i m p o r t a n t  in the clearance of LDL from 
the plasma. A d m i n i s t r a t i o n  of RE cell activity 
inhibiting agents causes a decrease in the rate of 
the clearance of the lipoprotein. Kinetic analysis 
shows that this was due to a decrease in LDL-receptor- 
independent catabolism.
3) L i p o p r o t e i n  c a t a b o l i s m  by c u l t u r e d  m a c r o p h a g e s  is 
down regulated by RE system suppressants. Incubation 
of m a c r o p h a g e s  wit h  these agents reduces the amount 
of LDL and 8-VLDL c a t a b o l i s e d  by the cells. This  
supports the in vivo findings.
4) -aflte^ed in the-, plasma . 6i ’! RE,.; ' t:locked
\/It"has an •deheitÿy^ àÿï'l'ncreased
^e^(^rb^or%t'ic 'Aroh-illty ( change-)'/ - any* in-
j^ ï^fea^ Sed cholesterol to protein ratio and is cleared 
the plasma more rapidly than normal LDL . ■ 
j-Cotittol LbL injected; i n t o , RE S<jppressed ahimals 
*aSsume'S <the-chatact-e-risticé- o.f thi^ • abhbriïlal*^ lipo-
 ^ ' . "
5) B l o c k i n g  the RE sy s t e m  of c h o l e s t e r o l  fed animals 
appears to promote the athe r o m a t o u s  infiltration of 
their aortae. Plasma c h o lesterol levels in the RE 
blocked "animals were not significantly different from 
those in cholesterol fed animals with functional RE
XXlll.
systems but the overall negative charge of their LDL 
was greater.
6) It f ollows that the RE system is working to clear an 
abnormal form of LDL which may be formed by "ageing" 
in the c i r c u l a t i o n .  P o t e n t i a l l y  this LDL is 
c a t a b o l i s e d  by a t h e r o s c l e r o t i c  p l a q u e s  l eading to 
lesion advancement.
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INTRODUCTION
1.1:
Ischaemic heart disease (IHD) accounts for more deaths in 
the "western" industrialised world than any o t h e r  single 
cause. For example. Levy reported in 1981 (1) that over 
a million people in the United S t a t e s  suffered a heart 
attack in 1978 with 650,000 mortalities. This compares to 
400,000 deaths from all forms of c ancer combined. IHD 
c o sts the U nited States 60 thousand million dollars per 
year in health care costs, lost w a g e s  and p r o d u c t i v i t y  
(2) .
The rest of North America and most of Europe 
and Australasia suffer similar human and monetary losses. 
W i t h i n  the United Kingdom, S c o t l a n d  has the h i g h e s t  
mortality rate from IHD with over 1 8 ,300 deaths in 1983 
(356 de a t h s  per 100,000 p o p ulation, male and female) 
compared with 14,200 from cancer (276 deaths per 100,000 
population, male and female) (3), (Table 1).
Although the m a j o r i t y  of people e x h i b i t i n g  
s y m p t o m s  of IHD (such as angina, myocardial infarction 
and sudden death) are over the age of 55 years (Table 2) 
it is u n d e r s t o o d  that the under l y i n g  a t h e r o s c l e r o s i s  
d e v e lops, unobserved, at a much earlier stage. This 
presents difficulties in elucidating the aetiology of the 
d i s e a s e .
TABLE 1
CAUSE
OF
DEATH
TOTAL
DEATHS
1982
TOTAL
DEATHS
1983
MALIGNANT
NEOPLASMS
14077 14210
ISCHAEMIC
HEART
DISEASE
18633 18335
Deaths from IHD compared with those from 
all forms of cancer in 1982 and 1983.
The death rates from IHD make Scotland 
the worst affected country in Britain.
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1.2; Atherosclerosis.
Before discussing those factors which are believed to be 
responsible for the initiation and advancement of the 
atherosclerotic lesion it would be advantageous to define 
the structure of arteries. The artery wall consists of 
three morphologically distinct layers, the intima or 
innermost layer, the media and the adventitia (Figure 1).
The intima is bounded on the lumen side by a 
monolayer of endothelial cells and separated from the 
media by a sheet of fenestrated elastic tissue known as 
the inner elastic lamina. The space between these 
boundaries is filled with connective tissue surrounding, 
in younger people, the occasional smooth muscle cell 
(SMC). The number of these SMC increases with age 
resulting in a thickening of the intima. It is here in 
the internal elastic lamina. The space between these 
formed. The current counsel is that damage to the vessel 
wall first occurs to the endothelial cells which afford 
protection from abnormal intrusion of blood components. 
Functioning normally, these cells allow metabolic exchange 
to occur between the blood and the vascular cells (4,5). 
Chemical, mechanical and immunological insults can disrupt 
this barrier and initiate the development of the lesion. 
The media may sustain secondary changes, especially in the 
more severe types of lesion.
There are three classically recognised types 
of lesion; 1) the fatty streak, 2) the fibrous plaque and
3) the complicated lesion.
FIGURE 1: Diagmatic representation of a
section through the wall of 
the aorta.
A; Intima
B; Media
C: Adventitia
D: Endothelium
E; Internal Elastic Lamina
F: Smooth muscle cell
G; External Elastic Lamina
H; Fibroblast
3.
The first of these is common in people over 
the age of 10 years (6). It does not generally interfere 
with blood flow because of its flattened topography. The 
yellow colour of the fatty streak is due to both intra- 
and extracellular lipid deposits. Intracellular deposits 
are mainly contained in macrophages and smooth muscle 
cells (7). These cells are thought to be the source of 
foam cells found in many lesions (8). The lipid
deposits, mainly cholesterol and a cholesteryl ester, are 
derived from the circulating pool in the blood. Endo­
thelial cells covering some of the lesions have a greater 
volume of cytoplasm than those over normal intima (9), 
though the significance of this fin-ding is not under­
stood.
Fatty streaks may be the precursors of the 
second type of lesion, the fibrous plaque for two main 
reasons; a) their lipid rich nature and b) the similarity 
in distribution of the tv70 types. This connection has, 
however, been disputed because some workers have found 
fibrous plaques occurring in sites normally unaffected by 
fatty streaks (10),
Fibrous plaques are whitish in colour and are 
implicated, through their elevated structure, in inter­
ference with blood flow which may lead to tissue 
ischaemia. The media plays an important role in the 
formation of these plaques. Smooth muscle cells from the 
media accumulate and proliferate in the intima, 
contributing to the raised nature of the lesion. The
4.
reasons for the elevation of the intima are, therefore, 
threefold; 1) migration and proliferation of smooth 
muscle cells from the media and macrophages from the 
blood born monocytes, 2) deposition of extracellular 
matrix components and 3) expansion and necrosis of the 
core of the plaque.
Smooth muscle cells and macrophages in the 
lesions are rich in lipid. As with the extracellular 
deposits the lipid present in these cells is mainly 
cholesterol and cholesteryl esters. , In the early form of 
the fibrous plaque the intracellular ester is mostly 
cholesteryl oleate, presumably produced by the action of 
ACAT within the cell. This means that, at this stage, 
the smooth muscle cells hydrolyse cholesteryl ester 
obtained from the plasma and re-esterify the free 
cholesterol with oleic acid as do normal cells. In more 
advanced plaques, however, the metabolic efficiency of 
the cell is reduced and the ester which accumulates is 
predominantly linoleate, the most common ester found in 
plasma lipoproteins (11).
Free cholesterol also plays an important part 
in the progression of the plaque.' It has been suggested 
by Jackson and Gotto (12) that initially, free cholesterol 
is incorporated into the cellular membranes decreasing 
their fluidity and further reducing the metabolic 
efficiency of the cell. Once the cellular assimilation of 
free cholesterol has reached the level of supersaturation 
of intracellular membranes, cholesterol can partition into
5,
crystalline structures of cholesterol monohydrate (18). 
This contributes to the destruction of the cell and 
necrosis of the lesion.
The lipid laden cells promote the development 
of a fibrous capsule which eventually surrounds the 
lesion and envelopes the necrotic core of extracellular 
lipid and cell debris.
The third and most advanced type of lesion, 
the complicated lesion, is characterised by the presence 
of calcification. Indeed they are thought to develop by 
a combination of haemorrhage, cell necrosis, mural 
thrombosis and calcification.
1,3: Current Hypotheses of Lesion Initiation and
Advancement.
1.3.1: The Endothelial Cell Injury Hypothesis.
An early form of the hypothesis was outlined by Virchow in 
1856. Since then it has been modified and updated but the 
original concept remains the same. In essence the 
hypothesis states that the endothelial barrier protecting 
the intimai layer is breached allowing contact with 
factors from the blood such as platelets, monocytes and 
lipoproteins. This results in the proliferation of 
smooth muscle cells, formation of foam cells and other 
biochemical and cellular sequelae described in section 
1 .2 .
E n d o t h e l i a l  cells are known to be injured by 
v a r i o u s  factors including m e c h a n i c a l  forces (13,14),
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chemical agents, such as lipoproteins (15) and immuno­
logical factors (16), The injury leads to adherence of 
platelets and monocytes to the unprotected connective 
tissue matrix of the mid-intima. According to Ross, 
monocytes are then activated to become macrophages and 
migrate into the intima releasing macrophage derived 
growth factor (MDGF) (17) which adds to the effect of 
platelet derived growth factor (PDGF) released from the 
adherent platelets (19). These growth factors stimulate 
smooth muscle cells to migrate through the inner elastic 
lamina and proliferate in the intimai layer, they also 
increase the number of lipoprotein receptors expressed on 
the surface of the cells. The smooth muscle cells 
synthesise and secrete connective tissue which is laid 
down in the intima. Rapid thickening of the intima and 
lipid deposition ensues.
In an attempt to repair the damage the 
endothelial cells bordering this area migrate over the 
intimai surface (20). If the migration is insufficient to 
cover the lesion, the endothelial cells divide. In cases 
where the extent of the injury and the tissue response to 
that injury are limited the endothelium will be successful 
and the lesion regresses. If, on the other hand, the 
damage is more severe and the endothelial layer is left 
incomplete, further cycles of smooth muscle cell 
proliferation and lipid deposition occur and the lesion 
recognisable as atheroma results.
7.
What causes the failure of the endothelial 
cells to recover the intima? At sites where the injury 
is continuous, such as mechanical injury due to hyper­
tension, the endothelial cells try repeatedly to cover 
the exposed mid-intima. They are capable of only a 
limited number of divisions, after which they can no 
longer respond in this way to aid in re-endothelial- 
isation. Thus cell senescence may play an important role 
in a long term cycle of damage and repair.
1.3.2; The Lipid Hypothesis
The lipid hypothesis states that lipoproteins can cause 
atherosclerosis without the involvement of other risk 
factors. This does not mean that other risk factors are 
not present or indeed contributory to atherogenesis and 
lesion advancement. Lipoproteins, which will be more 
fully discussed in a later section, are responsible for 
the transport of lipid, including cholesterol, in the 
plasma. The lipoproteins which are most frequently 
documented as being atherogenic are low density lipo­
proteins (LDL) but other lipoproteins, such as beta 
migrating very low density lipoproteins (eVLDL) and the 
remnants of chylomicrons and VLDL may be equally as 
potent.
There is extensive literature to support the 
lipid hypothesis covering many years. Anitschkow and 
Chatlow showed in 1913 that feeding a cholesterol rich 
diet to rabbits accelerated the development of athero­
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sclerosis and following this observation much work has 
been done in animals and humans to confirm and expand the 
finding. In animals, including non-human primates, the 
experimentally induced lesions, produced by feeding a 
diet which increases the plasma cholesterol level, 
closely resemble those found in humans (21,22). It has 
been shown that cholesterol in the atherosclerotic 
lesions of both animals (24) and man (25) is derived from 
the plasma. Using immunofluorescence techniques. Smith 
(23) demonstrated that LDL itself is present in these 
lesions and further investigation by Walton (26) revealed 
that most of it is extracellular and intact. An earlier 
investigation by Smith (27) showed tha't the concentration 
of LDL in the intima in atherosclerotic regions is 
proportional to the plasma LDL concentration and accord­
ing to Katz (28), by the age of 40 years, 72% of the 
intimai lipid and even higher percentages of the lipid in 
the lesions is plasma derived.
In a person with hyper1ipidaemia, damage to 
endothelial cells results in the formation of athero­
sclerotic plaques at a much more rapid rate than in those 
with normal plasma lipid levels (Fig. 2) (29,30) and, as
has been stated, lipoproteins themselves can damage the
endothelial monolayer (15).
Strong evidence for the lipid hypothesis 
comes from genetically determined abnormalities of the 
lipid transport system. Patients with familial hyper- 
cholesterolaemia (FH) have grossly elevated plasma LDL
FIGURE 2: The Lipid Hypothesis.
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Left;- the relation between serum cholesterol levels 
in man (30-49 years) and their relative risk of 
coronary heart disease (•) and a curve of best fit 
to the data (o), from Framingham data (101).
Right:- the lipid hypothesis proposes that lowering 
serum cholesterol level from A to B reduces the relative 
risk from X to Y.
TABLE 3;
PERCENT
REDUCTION
IN
LDL
CHOLESTEROL
TOTAL
CHOLESTEROL
REDUCTION 
OVER 
CONTROL 
GROUP IN
RISK OF IHD 
OR SUDDEN 
DEATH
POSITIVE
EXERCISE
TEST -
ANGINA
CORONARY
BYPASS
ŒuIÆBrntAMINE
GROUP
20.3
13.4
PERCENT CROP I N  
OÜLESTYRAMENE  
GROUP OVER 
PLACEBO
19
25
20
21
PLACEBO
GROUP
7.7
4.9
Reduction in cholesterol level reduced the risk 
of heart disease.
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levels, indeed those with the homozygous abnormal form of 
FH frequently suffer their first myocardial infarction 
before the age of fifteen years and rarely survive past 
their late twenties. Patients aged between 5 and 10 
years who have IHD are unlikely to have been exposed to 
other risk factors such as hypertension and cigarette 
smoking (31).
Further evidence was obtained from epidemi­
ological studies undertaken in Japan. Here hypertension 
and cigarette smoking are greater than in the West but 
Robertson showed that plasma cholesterol levels and the 
incidence of heart disease are lower. He speculated that 
other risk factors may not operate, or operate at much 
reduced levels, if plasma cholesterol is not raised (32).
Until recently clinical trials, undertaken to 
show a relationship between reducing cholesterol levels 
and lowering incidence of heart disease, have been incon­
clusive. It has now been shown that a moderately low 
cholesterol diet in tandem with an oral bile acid 
séquestrant reduced the cholesterol level in the plasma 
of asymptomatic men with hypercholesterolaemia by 8%. LDL 
cholesterol levels were reduced by 11% with a concomitant 
drop of 19.0% in the risk of contracting coronary heart
disease (33) (Table 3).
In this section the lipid hypothesis has been
examined independently but perhaps it should be viewed 
with other existing hypotheses to gain fuller insight 
into the causes and effects of atherosclerosis. Elevated
10
LDL levels can damage endothelial cells (15) and thus 
cause an increase in LDL infiltration into the vessel 
wall and in platelet adherence and aggregation. Indeed, 
Carvalho et al (34) has reported that hyperlipoprotein- 
aemia may induce platelet aggregation and the release of 
PDGF. It is possible that this contributes to athero­
genesis in patients with hyperlipbproteinaemia even if the 
extent of injury to the endothelium is modest._____________
Evidence is now available which shows that 
injury to the endothelial transport barrier, even if the 
cells are not stripped off, will cause an increase in the 
rate of infiltration, cellular uptake and degration of 
LDL at any given plasma lipoprotein level. Platelet 
derived growth factor causes an increase in the number of 
sites on smooth muscle cells by which LDL is actively 
taken up (36). Stimulation of smooth muscle cell growth, 
which can occur as a result of interaction with LDL as 
well as growth factors, causes the deposition of large 
amounts of extra cellular matrix components, most notably 
glycosaminoglycans, which can trap LDL in the extra­
cellular spaces of the intima (38).
Thus, a l t h o u g h  there is good evide n c e  for 
i n d i v i d u a l  hypotheses, perhaps a compromise between them 
g i v e s  a more r e a listic, overall p icture of a t h e r o ­
sclerosis.
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Plasma Lipid Transport: The Lipoproteins.
2  ^* Nomenclature of the Lipoprotein Classes.
Various methods for isolating the classes of lipoproteins 
will be discussed in a later section but at this point it 
is necessary to mention only one of these; density 
gradient ultracentrifugation. Due to their lipid 
content, lipoproteins have a low buoyant density which 
allows them to be isolated by flotation through a salt 
gradient.
Five major classes of lipoprotein (39) have 
been identified in human plasma. These are i) chylo­
microns; density range <0.95 kg/1: ii) very low density 
lipoproteins (VLDL); density range 0,95 - 1.006 kg/1:
iii) intermediate density lipoproteins (IDL); density 
range 1.006 - 1.019 kg/1: iv) low density lipoproteins 
(LDL); density range 1.019-1.063 kg/1; and v) high
density lipoproteins (HDL); density range 1.063 -
1.210 kg/1 (Table 4).
Each class has a characteristic composition 
and metabolic fate although most of its c o m p onents are 
not fixed but e x ist in a state of dynamic equilibrium, 
exchanging freely between fractions.
Lipoproteins with similar density ranges are 
found in other mammals but their relative amounts and 
compositions may vary (40).
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^ ^  Composition of Lipoproteins.
As the name suggests lipoproteins are composed of a 
mixture of lipids and proteins. The relative proportions 
and types of lipid and protein in each lipoprotein 
determines the fraction in which it will be found. 
Chylomicrons, for example, have a large triglyceride 
component and a low content of protein. The triglyceride 
content decreases and that of cholesterol and protein 
increases as the density of the particle increases 
(Table 5).
The protein component, apolipoproteins or 
simply apoproteins, are named alphabetically according to 
the classification proposed by Alaupovic (41). Different 
lipoprotein fractions have characteristic apoprotein 
contents (Table 5). It is likely that the apoproteins 
direct the metabolic fate of the lipoprotein. VLDL, for 
instance, is a substrate for lipoprotein lipase which 
removes triglyceride from the particle by hydrolysis. 
This reaction, however, only proceeds in the presence of 
one of the apolipoprotein C peptides, apoCII, which is an 
activating cofactor for the enzyme. Absence or dys­
function of apoCII results in an accumulation of VLDL and 
chylomicrons, the triglyceride of which is also 
hydrolysed by lipoprotein lipase, in the plasma (42).
2,3; The Structure of Lipoproteins.
Transport of hydrophobic lipids through the aqueous 
medium of the plasma poses a structural problem in the
TABLE 5:
CLASS DENSITY
(kg/1)
MAJOR
LIPIDS
APO­
PROTEINS
CHYLO­
MICRONS < 0.95
TRIGLYCERIDE
90% A,B,C
VLDL
0.95 - 
1.006
GLYDEEUDE 60% 
HCSHÜLIPID 15% 
aOJESTEFGL 20%
B,C,E
IDL
1.006 - 
1.019
GLYŒKŒE 35% 
CHOLESTEROL 45% 
EHDSÎHDLIPID 15%
B,C,E
LDL
1.019 - 
1.063
CHXESTEROL 60% 
IHDSEHOLrPID 15%
B
HDL
1.063 - 
1.210
EHOSLTOLTPID 40% 
CHOLESTEROL 40%
A,C,E
Composition of the lipoprotein classes.
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organisation of lipoproteins. Non-polar lipids, such as 
triglycerides and cholesteryl esters, are completely 
insoluble in aqueous solution and cannot be carried in 
free form. Amphipathic lipids, such as phospholipids and 
free cholesterol, contain both polar and non-polar 
regions within their structure and can therefore interact 
with both hydrophobic and hydrophilic environments. These 
lipids form the outer shell of the lipoprotein, their 
hydrophobic regions interacting with the non-polar core 
of triglyceride and cholesteryl esters and their hydro­
philic region with the plasma (Fig. 3). The apoproteins 
are found associated with the shell of phospholipids and 
free cholesterol.
Sequence analysis of certain of the apo­
proteins reveal an unusual alpha helical structure. 
These helices, known as amphipathic helices (43), have 
hydrophobic and hydrophilic faces. The hydrophobic face 
is believed to interact with the non-polar regions of the
phospholipid shell.
Apoproteins C and E appear to be only loosely 
attached to the lipoprotein and exchange freely between 
I ipoprote ins of the same and different classes. ApoB, 
however, seems to be an integral component of the 
lipoprotein and exhibits no such exchange.
2.4: The Apolipoproteins (Table 6) 
i) ApoAI
ApoAI is a single polypeptide chain with 243 amino acids
Fig. 3 : Diagramatic representation of generalised
lipoprotein structure.
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phospholipid 
triglyceride 
cholesterol ester 
free cholesterol 
apoprotein
Apolipoproleifi Molecular 
Wt. X 10
Site «f 
Synlliesis
Scnim
Concentration
(iiiK/dl)
Function
A l 28.J Intestine
Liver
1 0 0 - 150 Colactor o f lecithin :cholesterol acyllransfcrasc; 
structural protein ol 1 ID L
A  II 17.0 Intestine
Liver?
3 0 - 50 I'hospholipiil-binding properties; structural 
protein o f H D L
A -IV — 46.0 Intestine 15 Unknown
U-IÜO 549 Liver 80 - 100 Intracellular formation or transcellular transport o f 
V L D L ; receptor interaction (L D L ) with 
’‘apolipoprotein 11, E receptor cells"
U 48 - 2 6 5 Intestine 
Liver ?
1 Intracellular formation or transcellular transport o f 
chylomicrons and V L D L ; receptor interaction with 
“apolipoprotein 11, E receptor cells"?
C l 6.5 Liver < 1 0 Cofactor o f lipoprotein lipase o f adipose tissue 
(particularly saturated fatty acids)
C -ll 8.8 Liver 3 - 8 Cofactor o f lipoprotein lipase o f adipose tissue
C - I I I0...2 8.9 Liver 8 - 15 Unknown
D 20 7 10 - Unknown ; some question o f a role in L C A T  reaction 
and metabolism of cholesteryl esters
E 39.0 Liver 3- 5 Receptor interaction with “apo 13, E receptor cells" 
and with hepatic apo E receptors; inhibitor of 
lipoprotein lipase o f adipose tissue?
Chylo­ VLDL LDL HDL; HDLj
microns
% % ■% % %
A - I 33 trace trace 65 62
A -1 1 trace - _ trace trace 10 23
A - I V 14 - ? trace
B 5 25 95 3
'
C 32 55 2 13 5
D ? 7 ? 2 4
E 10 15 3 3 1
other 6 5 5 4 5
TABLE 6: The Apolipoproteins.
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and a molecular weight of 28,500 daltons. The protein 
has no cystine or leucine and there are no carbohydrate 
residues linked to the peptide chain. It is rich in 
amphipathic helix and avidly binds phospholipid (44).
i i ) ApoAII
ApoAII consists of two identical polypeptide chains 
linked by a single disulphide bridge at cystine-6. Each 
polypeptide has 77 amino acid residues giving a total 
molecular weight of 17,500 daltons. The molecule is 
devoid of histidine, arginine and tryptophan and, like 
apoAI, has no carbohydrate side chains. ApoAII has less 
amphipathic helix and more disordered structure than 
apoAI but still avidly forms phospholipid complexes (44).
iii) ApoAIV
Little is known about apoAIV except that it has a 
molecular weight of 46,000 daltons and that it is freely 
soluble in aqueous solution, indeed the majority may 
exist unassociated with plasma lipoproteins.
iv) ApoB
ApoB is extremely insoluble in aqueous solution after the 
removal of associated lipids. It can be solubilised with 
high concentrations of detergent, such as sodium dodecyl 
sulphate, though it is likely that aggregates form under 
these conditions. Estimates of molecular weight range 
from 10,000 to 550,000 daltons. Kane et al have isolated 
four species of apoB (45) which are named, after their 
electrophoretic mobility in sodium dodecyl sulphate
1 5 .
polyacrylamide gel electrophoresis (SDS PAGE), by a 
cent i1e system. ApoB 100 has an apparent molecular 
weight of 550 ,000 daltons and is predominant in LDL and 
VLDL. It appears that this form of apoB is synthesised 
mainly in the liver and, as the major form of apoB in 
LDL, shows that chylomicrons are unlikely to be the 
precursors of higher density lipoproteins (46). Two 
other forms of apoB are reported to be found on LDL, 
apoB74 and apoB26. These may be complimentary fragments 
or components of apoBlOO but are as likely to be arti­
facts.
ApoB48, molecular weight 260,000 daltons, is 
the major species present on triglyceride rich particles 
produced by the gut. The synthesis of apoB48 is 
independent of that of apoBlOO (46) and occurs in the 
gut. Unlike apoB74 and apoB26, no component can be added 
to apoB48 so that it has the same amino acid composition 
as apoBIOO. There are also differences in the absolute 
amounts of certain amino acids present (45). Krishnaiah 
et al (47) showed that this kind of heterogeneity alao 
occurs in other mammals, including the rat.
Although apoB is a structural protein in 
chylomicrons, VLDL and IDL, upwards of 90% of apoB is 
found in LDL in normal individuals.
v) ApoCI
ApoCI activates the enzyme lecithin : cholesterol acyl- 
transferase (LCAT) although the in vivo significance of 
this cofactor activity remains to be determined. Ten
16
percent of the total apoprotein content of VLDL and 
approximately two percent of that of HDL is apoCI. The 
amino acid sequence of apoCI is known and the protein has 
been synthesised in the laboratory (48). Like apoA, 
apoCI avidly binds phospholipid. The binding region in 
apoCI has been identified as a peptide of 26 amino acids 
occurring between residues 32 and 57 in the peptide 
chain.
vi) ApoCII
As stated in section 2.2 apoCII is a specific cofactor 
for lipoprotein lipase. The apoprotein comprises ten 
percent of VLDL protein and approximately 1.5 percent of 
HDL protein. The phospholipid binding region and the 
lipoprotein lipase cofactor region are separate domains. 
Like the other apoC proteins apoCII is transferred easily 
among the triglyceride rich lipoproteins and HDL.
vii) ApoCIII
ApoCIII can be resolved into three distinct bands on 
polyacrylamide gel electrophoresis. These bands are 
designated apoCIIlQ, CIIIi and CIII2 and differ in their 
content of sialic acid. ApoCIII comprises about 50-g of 
the total apoprotein content of VLDL in normal 
individuals but a higher percentage of apoCIII is found 
in those suffering from h y p e r t r iglyceridaemia. It has 
been found that apoCIII inhibits lipoprotein lipase under 
certain in vitro conditions but the relevance of this 
finding in vivo remains to be determined (49),
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viii) ApoD
This apoprotein is also known as apoAIII. It is found 
mostly associated with HDL, though contributes less than 
five percent of the protein mass. Chajek and Fielding 
attributed to apoD the role of cholesteryl ester transfer 
Protein (50) which transfers newly synthesised cholesteryl 
esters from HDL to LDL and other lipoproteins (Fig. 4). 
This view was later disputed by Morton and Zilversmit (51) 
after separation of apoD from the cholesteryl ester 
transfer protein.
ix) ApoE
Human apoE has a molecular weight of 36 ,000 daltons and 
contains 299 amino acids. Approximately 10 percent of 
these are arginine residues and for this reason the 
apoprotein is often termed "arginine rich apoprotein". In 
chylomicrons and HDL a portion of apoE is found complexed 
with apoAII (54). The structure of mature apoE and that 
of a precursor form, found at the site of synthesis in 
the liver, is known (52,53). ApoE is a glycopeptide and, 
after the removal of sialic acid residues, can be 
resolved into four major bands by isoelectric focusing 
(55). These bands are designated apoE-1, E-2, E-3 and 
E-4. It is thought that apoE-1 is the result of post 
translational modification but that apoE—2, E—3 and E—4 
are genetically determined human mutations (56).
ApoE-3 is the "wild type" normal apoprotein 
being present as apoE3/3 in 51% of the population with a 
gene frequency of 0.71. ApoE-4, although a mutant, is 
not functionally different from apoE-3. The mutation of
FIGURE 4;
LDL receptor
CE
Cholesterol efflux
Choi ChoiLCAT- A p o A I-A p o D  
cholesteryl ester transfer protein
LDL Remnants
CE
HDL
Chylomicrons,
VLDL
The role of ApoD in the transfer of newly synthesised 
cholesteryl ester from cells and HDL to other lipo­
proteins. ApoD is represented here as a separate 
entity to Cholesteryl Ester Transfer Protein 
(Zilversmit, ref.51).
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apoE-3 which produces apoE-4 is a single amino acid
substitution at residue 112 of the primary sequence in 
which the cystine residue normally present is converted 
to an arginine residue. The functional normality of 
apoE-4 reflects the fact that this substitution does not 
alter the structure of the protein significantly nor is 
it in such a position as to interfere with binding of 
apoE to its receptor.
ApoE-2 is functionally different from apoE-3 
in the respect that it does not react with the apoE 
receptor. The first apoE-2 variant was detected using 
isoelectric focusing and was discovered to contain a 
single amino acid substitution ‘ at residue 158. At this 
site the arginine residue normally present was replaced 
by a cystine residue (57) (Fig. 5). Further apoE-2 
variants, which are isoelectrically silent because the 
amino acid substitutions do not cause changes in overall 
charge, have also been found. The most important of 
these are apoE-2 in which the lysine residue at position 
146 is replaced by glutamine, termed apoE-2 (Lysias ->Gln) 
and one in which the arginine residue at position 145 is 
replaced by cystine termed apoE-2 ( Arg-] 4 5 ->Cys) (58).
ApoE-2, with its inability to react with 
lipoprotein receptors, has been implicated in the 
aetiology of the disease known as type III hyperlipo- 
proteinaemia noted for the accumulation of an abnormal 
VLDL, known asS-VLDL, with a high concentration of 
apoE-2. Most individuals with this disorder have the
f i g u r e  5:
Diagrammatic representation of a Corey- 
Pauling-Koltun space filling model of residues 
132 to 164 of human apoE3. This highlights 
the binding domain of apoE and the amino acids, 
important to that binding, which, if substituded, 
lead to defective apoE-receptor interactions.
19
E-2/2 ptienotype but not all of the people with the E-2/2
phenotype have type III hyperlipoproteinaemia suggesting 
that other factors are necessary for the manifestation of 
the disorder (59).
3: Lipoprotein Metabolism
3.1: Lipoprotein Receptors: ApoB and ApoE .
i ) The LDL receptor
Since the discovery of the LDL receptor by Goldstein and 
Brown in fibroblasts (61) it has been found in other cell 
types, such as arterial smooth muscle cells, adrenal 
cells, hepatocytes, lymphoid cells and on the membranes 
of freshly isolated blood lymphocytes and adrenal cortex 
(62).
The LDL receptor binds both apoB and apoE 
containing lipoproteins and it has been shown that it is 
these apoproteins which are responsible for the binding 
of the lipoprotein to the receptor (63,64).
The receptor itself is a transmembrane 
protein of the plasmalemma which is synthesised in 
membrane associated ribosomes (65). It is glycosylated 
in the Golgi Apparatus before associating with the 
membrane in a random distribution. The protein has two 
active domains: a binding domain, to which the lipo­
protein attaches, and an internalisation domain on the 
inner surface of the plasmalemma. The internalisation 
domain is believed to have a high affinity for clathrin, 
another membrane protein. Clathrin is found in regions
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of the membrane known as coated pits which cover no more 
than two percent of the total cell surface. Although the 
newly synthesised receptors associate randomly with the 
membrane, more than 60% of them are found in coated pits, 
probably due to the affinity between clathrin and the 
internalisation domain (66).
Endocytosis occurs by invagination of coated 
pits to form coated vesicles with a half life of approxi­
mately 5 minutes. The receptors themselves return to the 
membrane after the coated vesicle has fused with the 
primary lysosome (66).
The molecular weight of the receptor protein 
was originally estimated at 110,000 daltons by Mahley 
using the radiation inactivation method (67) and at 
160,000 daltons by Goldstein and Brown after purification 
of the receptor from bovine adrenal cortex (68).
The receptor is synthesised as a precursor 
with an apparent molecular weight of 120,000 daltons, as 
estimated by SDS-polyaery1amide gel electrophoresis. 
Within 30 minutes, the precursor undergoes several 
carbohydrate processing reactions in the Golgi apparatus, 
which results in the formation of the mature form of the 
receptor with an apparent molecular weight of 160,000 
daltons (69,137). The carbohydrate chains are pre- 
dominantly 0-1 inked to a region, near the carboxy 
terminus, which is rich in serine and threonine residues 
(Fig. 6) (137). The protein has been divided into
regions or domains. The first of these is a cysteine
figure 6 :
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rich region of 322 amino acids which is thought to be the 
ligand binding site. The cysteine residues, which occur 
approximately every seven amino acids, responsible
for the stability of the receptor, an important factor as 
it is recycled between coated pits on the surface and 
endosomes within the cell. This domain is also rich in 
aspartate and glutamate residues which, being negatively 
charged, may be responsible for the interaction with 
lysine and arginine residues of the ligand proteins; apoB 
and apoE (137).
Next is a domain of roughly 350 amino acids 
which has striking homology with the poly protein 
precursor of mouse epidermal growth factor. The reason 
for this is unclear but it may be that proteins for 
nutrient delivery and growth stimulation have a common 
evolutionary origin (137). The third, threonine and 
serine rich domain has been discussed and the fourth is 
the membrane spanning region of 2 2  hydrophobic amino 
acids. The carboxy terminal domain is 50 amino acids 
long and located on the cytoplasmic side of the membrane 
(137) (Pig. 6 ).
i i ) The Chylomicron Remnant Receptor
This hepatic receptor is responsible for the clearance of 
a p o E - r i c h  l i poproteins which include ch y l o m i c r o n 
r e m n a n t s ,  8-VLDL and a species of HDL, which is rich in 
apoE, called apoE HDLc. if the LDL receptor was of major 
i m p o r t a n c e  in the clearance of apoE containing l i p o ­
p r o t e i n s  it might be expected that the lack or
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dysfunction of these receptors, such as in familial 
hypercholesterolaemia, would cause an increase in the 
plasma concentrations of the apoE rich lipoproteins. 
This, however, is not the case (138), leading, origin— 
ally, to the suspicion that the chylomicron remnant 
receptor might exist.
Further evidence for its existence was 
obtained in experiments with mature dog hepatic 
membranes. It was shown that the number of LDL receptors 
on dog liver declined linearly with age so that at 
approximately 20 months from birth the dogs had no LDL 
receptors in evidence on preparations of their liver 
membranes. The binding of apoB containing lipoproteins, 
such as LDL, declined colinearly. Chylomicron remnant 
receptors, as determined by subtracting the amount of 
apoE HDLc bound to the LDL receptors from the total 
amount of apoE HDLc binding, remained remarkably constant 
for all ages of dog. It was found that LDL-receptors 
present on the liver membranes of young dogs could be 
suppressed by feeding a diet supplemented with 
cholesterol but the chylomicron remnant receptors could 
not. In adult dogs, fasting induced the expression of 
LDL receptor but did not increase the number of chylo­
micron remnant receptors (71,72).
As with the binding of apoB to the LDL-
receptor, the binding of lipoproteins to the chylomicron
remnant receptor is protein mediated. Chemical
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m o d i f i c a t i o n  of apoE results in the loss of r e c e p t o r  
lipoprotein interactif! (70).
iii) The Macrophage Receptor for Acetyl-LDL
LDL that has been modified chemically with acetic 
anhydride n,o form acetyl —LDL (ac—LDL) is taken up with 
extremely high efficiency by macrophages. This uptake 
can result in a massive cholesterol accumulation within 
the c e l l s  which does not occur with native LDL (139). 
Studies with radiolabelled ac-LDL showed that the rapid 
u p t a k e  wa s  m e d i a t e d  by a receptor on the cell surface 
which recognised ac-LDL but not native LDL and that the 
binding of ac-LDL was abolished on treatment of the cells 
with low concentrations of trypsin or pronase (139,103), 
suggesting that the receptor was composed of protein.
A^etylatiif! of LDL removes po s i t i v e  char g e s  
from the etta amino groups of lysine residues in the 
protein moieties of lipoproteins thereby converting the m  
to a st r o n g l y  a nionic species (128) (Fig. 14), It is 
this incre a s e  in overall net negative charge w h i c h  is 
r e s p o n s i b l e  for the binding of ac-LDL to the macrophage 
receptor. Other chemical modifications which abolish the 
positive charge on lysine residues also convert LDL into 
a ligand for the ac—LDL receptor. Such ligands include 
c i traconylated LDL (103), maleylated LDL (139), succiny— 
lated LDL (139), m a l o n d i a l d e h y d e - t r e a t e d  LDL (140) and
acetoacetylated LDL (141),
B i n d i n g  to the ac-LDL r e c e p t o r  only occurs
when 30 moles of m o d i fying agent has been i n c o r p o r a t e d
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per mole of LDL. Below this threshold value no ligand 
- receptor interaction takes place and further, below 2 0  
moles of modifying agent per mole of LDL the native LDL 
receptor begins to bind the ligand.
The acetyl-LDL receptor has been found on 
macrophages from every source and species investigated 
including resident peritoneal macrophages from mice, rats 
and dogs (139,141), Kupffer cells from guinea pigs (139), 
monocyte derived macrophages from humans (139,140) and on 
established lines of mouse macrophage tumours such as 
J774 cells (142).
The bovine receptor has an estimated 
molecular weight of 283 ,000 daltons. .In contrast to the 
LDL receptor of non-macrophage cells the acetyl LDL 
receptor is not down regulated when cellular cholesterol 
concentration rises. As a result of their failure to 
suppress the production and utilisation of acetyl LDL 
receptors, macrophages continuously exposed to medium 
containing ac-LDL accumulate massive amounts of 
cholesterol, as much as 80% of which is cholesteryl 
ester, and are converted into foam cells (139) (section 
1.2 ).
Evidence that the acetyl LDL receptor is 
expressed in vivo comes from experiments done with I 
labeled chemically modified LDL which was injected into 
dogs (141) and mice (139). The labeled ligand was 
cleared from the plasma within minutes by the macrophages 
of the liver (Kupffer Cells)(144). The hepatic uptake of
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intravenously administered ^25i_a^etyl-LDL in mice was 
blocked by a simultaneous injection of fucoidin (139), a 
highly anionic protein which interacts with the acetyl- 
LDL receptor (139), confirming that the uptake was 
mediated by a saturable receptor with a specificity 
similar to the binding site demonstrated in vitro.
The normal ligand for the acetyl LDL receptor 
in vivo is unknown but several possibilities exist. 
Malondialdehyde, a biproduct of the oxidation of arachi- 
donic acid by platelets and macrophages,' is known to 
convert LDL into a form recognised by the acetyl LDL 
receptor (145). There are other substances derived from 
arachidonic acid which may also modify the etta amino 
groups of lysine residues removing their positive charge. 
These include prostaglandin A, 5-hydroxyperoxyeicosa- 
tetraenoic acid and leukotriene A 3 (146).
Henriksen et el have shown that cultured 
endothelial cells can convert human LDL into a form that 
is recognised by the acetyl-LDL receptor (142,147).
Incubation of LDL with one of several types of cultured 
cells including aortic endothelial cells, umbilical vein 
endothelial cells or aortic smooth muscle cells can 
induce the changes in LDL which leads to its recognition 
by the acetyl LDL receptor (147). They are not, however, 
induced by incubation of LDL with conditioned medium from 
these cells or by incubation with fibroblasts. The 
modified LDL has an increased density, owing to a 
decreased content of free and ester ified cholesterol and
26
an enhanced electrophoretic mobility, presumably due to 
an increased net negative charge (147).
Retroendocytosis, a process by which the 
cells endocytose LDL then return it to the medium without 
contact with primary lysosomes, is one possible mechanism 
by which the changes in LDL could occur. Indeed, 
incubation at 4 C, a temperature at which endocytosis 
does not occur, fails to modify LDL to a form which is 
recognised by the ac-LDL receptor (147).
iv ) The Macrophage Receptor for 3 -VLDL
6 -VLDL are not normally present in detectable amounts in 
the plasma of humans or animals but Mahley et al. 
(74,148) showed them to accumulate in the plasma of a 
variety of species, including dogs, rats, rabbits and 
monkeys, when the animals are fed a high cholesterol 
diet. They are found in the same density range as normal 
VLDL ( 0 . 95-1 . 006 kg/1) but, in contrast to normal VLDL, 
have a cholesteryl ester rich core and instead of the 
pre - 6 mobility on agarose gel electrophoresis associated 
with normal VLDL, have a p-mobility (148,82), (see also
section 3.3, ii).
3-VLDL particles are thought to represent
exaggerated forms of remnant particles which are normally 
created during the catabolism of chylomicrons and VLDL 
and are rapidly removed the liver (62,149). In
cholesterol-fed animals the clearance mechanism is 
overloaded and the remnants accumulate in the plasma.
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grow in size and become even further enriched in chol­
esteryl esters to form 3-VLDL (149).
Goldstein et al. (73) reported that mouse 
peritoneal macrophages express a surface binding site 
that mediates the uptake and degradation of B-VLDL. The 
receptor is specific for B-VLDL and does not bind acetyl 
LDL, normal LDL or normal VLDL (73,74). The B-VLDL 
receptor is expressed on the cell surface of monocyte 
derived macrophages from patients suffering from familial 
hypercholesterolaemia, a genetic disorder in which LDL 
receptors are not present, suggesting a different genetic 
locus for the B-VLDL receptor (74).
When the protein moieties of B-VLDL are 
modified by reductive méthylation, a procedure which 
prevents protein-receptor interaction in other lipo­
proteins, the binding of B-VLDL to the B-VLDL receptor is 
also abolished (150). The proteins of B-VLDL consist 
almost entirely of apoB and apoE yet LDL containing 
largely apoB and apoE HDLc containing largely apoE fail 
to inhibit the degradation of B-VLDL (73 ,74 ). Moreover, 
normal VLDL containing both apoB and apoE, fail to bind 
to the B-VLDL receptor (73) thus it has not been possible 
to determine which, if any, of the apoproteins mediates
the binding of B-VLDL to its receptor.
The B-VLDL receptor is only partially down 
regulated by the influx of cholesterol into the cell 
which may explain the continued accumulation of chol­
esteryl ester which leads to foam cell formation (73,74).
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3.2; Chylomicron Metabolism.
ChylomicLons are large (300-5,000Â diameter) triglyceride 
rich particles which are synthesised in the mucosal cells 
of the small intestine. When triglyceride is hydrolysed 
in the gut the free fatty acids and glycerol are absorbed 
by the mucosal cells, re-esterified and packaged into 
chylomicrons (60). Triglyceride accounts for more than 
83% of the weight of these lipoproteins, cholesterol for 
8 % and phospholipid for 7%. Protein in the form of apoAI, 
ATI, AIV and B-18 is present as only 2% of the total 
particle mass. ApoCI, CII, G U I  and apoE are transferred 
to the chylomicrons only after they enter the plasma 
(76,77).
The half life of chylomicrons in the plasma 
is only a few minutes. They are degraded by the action 
of lipoprotein lipase to core and surface remnants. The 
surface remnants are rich in phospholipids and free 
cholesterol as well as apoC and are partially transferred 
to HDL (78). Core remnants, more commonly known simply 
as chylomicron remnants, are rich in cholesterol ester 
and apoE and interact with the hepatic chylomicron
remnant receptors (70).
Chylomicrons, therefore, are responsible for
the delivery of exogenous cholesterol to the liver 
through chylomicron remnants and result in the down 
regulation of cholesterol synthesis by the liver in 
response to dietary intake (79).
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3.3: VLDL Metabolism.
i) Normal VLDL
VLDL, rather than being a single species, is a hetero­
geneous mixture of particles that have a hydrated density 
in the range 0 .95-1 . 006 kg / 1  and exhibit a 2 or pre - 3 
electrophoretic mobility. When VLDL is subjected to 
electrophoresis on starch block, most particles migrate 
in the same region as a2 ~globulin, hence the designation 
a 2 ~VLDL; this corresponds to the pre-g lipoprotein band 
observed on paper electrophoresis (82,148).
Over 90% of triglycerides found in fasting 
plasma are present in the form of VLDL which is 
synthesised and secreted by the liver (80,81). As with 
chylomicrons, VLDL interacts with lipoprotein lipase by 
virtue of the presence of apoCII. This results in the 
formation of IDL from the core remnants of VLDL and the 
surface remnants are recovered in the HDL density range. 
The reaction of VLDL with lipoprotein lipase is slower 
than for chylomicrons resulting in a plasma half-life of 
1-3 hours (83). HDL which has received free cholesterol 
from VLDL surface remnants interacts with lecithin- 
chole sterol a c y l  transferase (LCAT) which converts the 
cholesterol to cholesteryl ester using fatty acids from 
lecithin. These cholesteryl esters are transferred back 
to further enrich IDL through the action of cholesteryl 
ester transfer protein (50) (Fig.4, p.17 and Fig•  ^^  P -38^.
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Thus VLDL is metabolised to IDL by the 
hydrolysis and removal of its triglyceride and replace-
ment of this with cholesteryl ester.
ii) 3-VLDL
As has been discussed in section 3.1, iv) 3-VLDL has a 
hydrated density in the range 0.95— 1,006 kg / 1  and a 
p-^mobility on starch block electrophoresis (82, 148 ). It 
appears to be a remnant particle which is rapidly 
metabolised by hepatic remnant receptors and does not 
accumulate until this mechanism is saturated, as in the 
case of cholesterol feeding (74,148). 3-VLDL are also 
found in the plasma of humans with the genetic disease 
familial dysbetalipoproteinaemia or type 3 hyperlipo­
proteinaemia, a condition in which the removal mechanism 
for the remnants appears to be malfunctioning (151).
3-VLDL contains predominantly apoB and apoE 
with a reduced amount of apoC compared to normal VLDL and 
although it can interact with the LDL receptor and the 
chylomicron remnant receptor neither LDL nor apoE HDLq 
can inhibit the binding and degradation of 3 -VLDL by the 
macrophage 3-VLDL receptor (73,74).
Fai naru et al (152) showed that in dogs fed a die^ t 
rich in cholesterol and in humans with type 3 hyper— 
1 ipoproteinaemia the 3-VLDL isolated from the plasma 
could be separated into two fractions by agarose gel 
chromatography. The larger particles were designated 
. Fraction I (90-300 nm diameter) and had a lower protein- 
cholesterol ratio than Fraction II (30-70 nm diameter).
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On paper electrophoresis Fraction I remained at the
origin and Fraction II had mobility. Both fractions 
contained predominantly apoB and apoE but Fraction I was 
found to have a mixture of equal amounts of B-100 and 
B-48 whereas Fraction II contained only B-100. On the 
basis of these findings Fainaru suggested that Fraction I 
was of intestinal origin, ie that it was derived from 
chylomicrons, and that Fraction II was derived from VLDL 
produced in the liver (152).
Both particles interact with the 0 -VLDL 
receptor but Fraction I was 3-15 times more efficient at 
inducing cholesteryl ester synthesis (152) suggesting 
that the 3-VLDL receptor may preferentially interact with 
particles of intestinal origin.
In vivo the macrophage receptor may function 
as a backup mechanism to clear remnant particles which 
are not dealt with by their normal receptors. Mahley 
(148) showed that cholesterol-fed dogs develop massive 
cholesteryl ester deposition in macrophages throughout 
the body at plasma cholesterol levels exceeding 
750 mg/dl. This plasma cholesterol level is also the 
2 g ^ 0 2  Q 2, which 3—VLDL becomes a predominant lipoprotein 
(148).
Labelled 3-VLDL injected into animals are 
cleared rapidly from the plasma (84,153), Fraction I more 
rapidly than Fraction II (152). This rapid clearance is 
reduced if the B-VLDL are reductively methylated (150) or 
if the animals have been fed a cholesterol rich diet
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(153). These results are clouded by difficulties in 
interpretation because of the ability of 3-VLDL to bind 
to the LDL receptor of hepatic and other tissues 
( 74 , 1 53 ). Thus it is not certain that the 3-VLDL 
receptors of macrophages are responsible for the removal 
of 3-VLDL from the plasma.
3.4; IDL Metabolism
After the interaction of VLDL with the lipoprotein lipase 
of capillary walls and the removal of most of its 
triglyceride the product is a cholesteryl ester enriched 
lipoprotein designated intermediate density lipoprotein 
(IDL). These IDL particles are released into the 
circulation and have two possible metabolic fates:
i) conversion to LDL or ii) direct uptake and catabolism 
by the liver.
There is some evidence to suggest that direct 
catabolism by the liver is mediated through receptors. 
IDL contains both apoB and apoE and is thus eligible to 
interact with either the LDL receptor or the chylomicron
remnant receptor (62).
IDL which are not catabolised in this way
undergo a further conversion process in which most of the
remaining triglyceride and all of the apoproteins except
apoB are lost. The resultant particle, which is highly
enriched in cholesteryl ester and apoB, is termed low
density lipoprotein (LDL). The site of the final
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conversion of IDL to LDL is unknown, but it may occur in 
the liver sinusoids (8 6 ).
3.5: LDL Metabolism
LDL carries approximately two thirds of the cholesterol 
present in the plasma. Its major constituents are 
cholesteryl ester and apoB and its primary function is to 
supply cholesterol to extrahepatic tissues and to the 
liver. This is accomplished via the LDL receptor. After 
interaction with the receptors the LDL is internalised 
and degraded in the primary lysosomes. The cholesteryl 
esters are hydrolysed by an acid lipase and free 
cholesterol released for use in cellular reaction (87). 
This cholesterol has a marked effect on cellular 
cholesterol synthesis and further uptake of LDL by the 
receptors. The activity of 3-hydroxy-3-methyIglutaryl 
coenzyme A reductase (HMG CoA reductase), the enzyme 
which converts HMG CoA to mevalonate committing it to 
the de novo synthesis of cholesterol within the cell, is 
down regulated by cholesterol from degraded LDL particles 
at this level of enzyme synthesis (88,89). Although 
hydrolysed in the lysosome, cholesteryl ester is the main 
storage form of cholesterol within the cell and so must 
be re-esterif ied. This is done by acyl CoA : cholesterol 
acyltransferase (ACAT) which transfers oleate and 
palmitate onto cholesterol from their coenzyme A forms. 
ACAT is activated by the influx of cholesterol from LDL 
(90). Further influx and overloading of the cell by
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LDL-cholesterol is prevented by the down regulation of 
the synthesis of LDL-receptors by cholesterol (Fig. 7 ) 
(91 ) .
In individuals metabolising the lipoprotein 
normally, 33-66 percent of LDL is removed from the 
circulation by the receptor pathway. The range may seem 
broad but the actual figure varies among individuals, 
depending on the plasma concentration of LDL ie the pool 
size (92-94). In the disease familial hypercholesterol- 
aemia, which has a genetically determined lack of 
functional LDL receptors and experiences the gene dosage 
effect ( ie each gene of the pair produces protein hence 
in the heterozygous form one protein of each type is 
produced), heterozygous sufferers produce half the number 
of normally functioning receptors accounting for only 16% 
of overall LDL catabolism (94). These individuals have a 
raised plasma LDL cholesterol concentration, typically in 
the range 8-9 mmol/1 (300 mg/dl).
The homozygous form of the disease is 
manifested in a near complete lack or dysfunction of LDL 
receptors. This results in a greatly elevated plasma LDL 
concentration from an early age and typically, a 
myocardial infarction before thé age of fifteen years. 
These individuals are unlikely to survive their second 
decade (31).
Thus far three types of the homozygous forms 
of familial hypercholesterolaemia have been identified.
LDL Receptor#.
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Fig.7 : Sequential steps in the LDL receptor model.
HMG CoA Reductase hydroxymethylglutaryl
Coenzyme A Reductase
ACAT:- acy1-Coenzyme A: cholesterol acyl­
transferase.
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each resulting from a different mutation of the receptor 
gene (92).
i) receptor negative - this, the most common form, 
appears to result from a complete lack of receptor 
binding at the cell surface.
ii) receptor defective - in this type less than 2 0 % of 
normal binding occurs.
iii) internalisation defective - here normal amounts of 
LDL bind to the receptors but the cells appear to 
be incapable of internal is ing the LDL-receptor 
complex.
other mutations affecting LDL metabolism 
by cells have been found. They are autosomal recessive 
genetic disorders called Wolman's syndrome and chol­
esteryl ester storage'disease. In Wolman's syndrome (95) 
the absence of lysosomal acid lipase activity results in 
an inability to hydrolyse cholesteryl esters and tri­
glycerides. The build up of these lipids causes the 
formation of foamy, lipid laden cells and although 
sufferers have normal plasma lipid levels, they rarely 
survive past infancy.
Cholesteryl ester storage disease appears to be similar 
to Wolman's syndrome in as much as there is accumulation 
of cholesteryl esters and triglycerides in the absence of 
hepatic acid lipase activity. It has been suggested by 
Stone and Fredrickson (96) that the two diseases are 
caused by mutations of the same gene in wnicn bhe
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cholesteryl ester storage disease lesion is less severe 
resulting in a longer life expectancy (96),
There are at least two distinct mechanisms 
for the catabolism of LDL in vivo. The better understood 
of these is the receptor dependent mechanism described 
above (154) which is responsible for 33-66 percent of LDL 
clearance. It is therefore clear that a considerable 
amount of LDL is degraded by another mechanism(s),
Indeed in familial hypercholesterolaemia, 
discussed above, even more LDL is catabolised daily 
despite the near total lack of LDL receptors (92) 
(Fig, 8 ). This LDL receptor— independent catabolism has 
been termed the scavenger pathway, but the nature of the 
pathway has to be elucidated (155). It has been 
suggested that the cells of the reticuloendothelial 
system may be a major site of LDL catabolism in the 
absence of LDL-receptors (102). These cells have a 
greater capacity for non-specific uptake. Catabolism 
of LDL at a rate simply proportional to its concentration 
would be enough to yield preferential uptake by cells of 
the reticuloendothelial cells at higher plasma LDL levels 
(ie as found in familial hypercholesterolaemia) (155). 
Macrophages, an important component of the reticulo­
endothelial system, have receptors for negatively charged 
LDL (139,103, 128,140,141). There is some evidence for
the formation of such LDL in vivo (145) (section 3.1,
iii) by reaction with substances released on the 
oxidation of arachadonic acid. These negatively charged
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species of LDL are more likely to form when LDL remains
in the plasma for longer than normal amounts of time (ie 
in the case of familial hypercholesterolaemia) . Retro- 
endocytosis (a process of endocytosis and receptosome 
formation followed by exocytosis of the contents of the 
receptosome without contact with the lysosome), during 
incubation with cultured endothelial cells, can convert 
LDL into a form recognised by the same receptor as 
negatively charged LDL (142,147), again a process which 
is more effective in cases where LDL has an increased 
plasma half-life.
A further proportion of this LDL receptor- 
independent degradation will occur through fluid-phase or 
bulk endocytosis (156). Here LDL will be taken up by 
pinocytosis, along with other solutes, at a rate 
determined by its concentration in the plasma. This, 
however, does not make a major contribution to LDL 
receptor independent clearance as determined by Pittman 
in a rabbit model for familial hypercholesterolaemia 
using albumin as a determinant for bulk endocytosis 
(157).
The mechanisms discussed above may form all 
or more likely part of the LDL receptor-independent 
degradation of LDL which plays a significant part in the 
overall catabolism of that lipoprotein.
3.6: HDL Metabolism.
Throughout the conversion of VLDL to smaller, denser
3 8 .
particles the removal of core triglyceride there is a 
partial replacement of a portion of the triglyceride with 
cholesteryl ester probably through the action of 
lecithin-cholesterol acyl transferase (LCAT) and/or 
cholesteryl ester transfer protein.
Surface constituents from VLDL appear in the 
HDL density range. They may become associated with 
pre-existing HDL or may form new, nascent HDL. Such HDL 
is likely to exist as the heavier of the two HDL 
fractions, HDL3 (105). HDLg makes an ideal substrate for 
LCAT (106) resulting in its transformation to HDL2 . This 
conversion results in the transfer of cholesteryl ester 
back to VLDL or IDL with apoE acting as a carrier. As an 
alternative to the direct formation of HDL 3 , surface 
components from VLDL may interact with HDL2 to produce 
HDL 3 which is then metabolised as outlined above. It is 
conceivable that both mechanisms function simultaneously 
maintaining the HDL concentration in the plasma (Fig. 9).
Apart from its role as a catalyst in the 
metabolism of triglyceride rich lipoproteins, HDL has 
other properties. It can remove and incorporate 
cholesterol from cells in culture (107,108) and in the 
presence of acceptor HDL, macrophages hydrolyse chol— 
esteryl esters and excrete cholesterol (109) . It has 
also been implicated as a protective factor in the 
atherogenic process by inhibiting cellular injury which 
occurs when LDL is incubated with human endothelial cells 
(1 1 0 ) and partially inhibiting the uptake and degradation
FIGURE 9:
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of LDL by cultured smooth muscle cells and human fibre- 
blasts (1 1 1 ,1 1 2 ).
HDL was thought to be catabolised mainly by 
the liver but there is increasing amounts of evidence 
that catabolism also occurs in the small intestine (113), 
adrenal gland (114) and the kidney (115).
4 : Reticuloendothelial System
This is still the classically used name for this system 
but it has been criticised because reticuloendothelial is 
liable to be interpreted as excluding all but "reticulum 
cells" and "endothelial cells". The term is, however, 
generally understood to encompass cells which, by 
phagocytosis, can take up such substantial quantities of 
dye particles that their cytoplasm is conspicuously 
coloured; known as vital staining (158).
While reticulum cells are generally included 
in the system, endothelial cells, which lack the 
phagocytic activity which defines reticuloendothelial 
cells, are not. Reticulum cells are large, mononuclear 
cells associated with the connective tissue fibres of the 
lymphoid tissues. Because these cells have relatively 
little phagocytic capacity compared to tissue macrophages 
there is some doubt about the appropriateness of their 
inclusion in the reticuloendothelial system.
Tissue macrophages or histiocytes are 
amoeboid macrophages which are found free throughout the 
connective tissues of the body. They are probably the
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most numerous and certainly the most widespread of the 
reticuloendothelial cells (158). These cells are 
undoubtedly the macrophages from which foam cells are 
formed in atherosclerotic plaques (11,17). The alveolar 
macrophages of the lungs, peritoneal macrophages and 
macrophages found in other such cavities of the body may 
be considered to be tissue macrophages (158).
Endothelial macrophages is the term applied 
to phagocytes that line the lymph sinuses. They are also 
found distributed among the simple endothelial cells of 
blood sinuses (sinusoids) in certain organs, particularly 
the spleen, liver, pituitary gland and adrenal glands. In 
the liver these cells are known as Kupffer cells. The 
phagocytic activity of these macrophages differs from 
tissue to tissue showing little activity in the adrenals 
or pituitary compared to the liver and especially the 
lymph nodes and spleen (158).
Monocytes are of particular importance 
because they maintain the numerical strength of the 
reticuloendothelial system throughout the body. The blood 
borne monocytes are consistently in transit from the bone 
marrow, their tissue of origin, to make good damage or 
loss of reticuloendothelial cells. Only when the need 
for the macrophages is greatly increased and the monocyte 
replacement insufficient does proliferation of the cells 
already present occur (158).
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The relevance of the reticuloendothelial 
system to the metabolism of lipoproteins has been 
discussed in sections 1.3, 3.1 iii), 3.1 iv), 3.3 ii) and 
3.5.
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5: MATERIALS AND METHODS
5*1 ! Isolation of Lipoproteins,
5.1.1; LDL
LDL (density 1 . 030-1 . 050 kg/1) was isolated from human 
and rabbit plasma by rate zonal ultracentrifugation (117) 
through a linear salt gradient of d = 1 . 0 0  kg / 1  to 
1.30 kg/1 using a Beckman Ti14 rotor in an L5-65 ultra­
centrifuge. Rotor speed was maintained at 45,000 rpm for 
one hundred and ten minutes at a temperature of 15°C. 
Fractions which contained LDL were concentrated by 
pressure filtration (Amicon Corp., XM 100A filters) and 
dialysed against Buffer A (0.15 M NaCl containing 0.01% 
(0.1 g/1 ) disodium EDTA, pH 8.1). Alternatively the LDL 
was washed exhaustively in a pressure filtration unit 
(Amicon) using buffer A until the conductivity of the 
filtrate equalled that of buffer A (8-9 mMHO),
This method was superior to sequential 
flotation ultracentrifugation because of its speed and 
capacity for handling large volumes of plasma.
5.1.2: VLDL
Human and rabbit VLDL (density 0.95-1.006 kg/1) were
prepared by one of two methods:
1) Plasma was overlayered with density
1 .006 kg/ 1  sodium chloride solution and centrifuged for
18 hours at 39,000 rpm and 20°C using a Beckman Ti60
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rotor in an L5-65 ultracentrifuge. The VLDL isolated by 
this method was washed by a second centrifugation through 
density 1.006 kg / 1  sodium chloride solution at
39.000 rpm. The VLDL was finally dialysed against 
buffer A (section 5.1.1),
2) Plasma subjected to zonal ultracentri­
fugation, as described in section 5 .1 .1 , yields fractions 
containing VLDL (Fig. 10). These fractions were 
collected, overlayered with density 1.006 kg / 1  sodium 
chloride solution and centrifuged for 18 hours at
39.000 rpm and 20°C using a Beckman Ti60 rotor in an 
L5-65 ultracentrifuge. The isolated VLDL was dialysed 
against buffer A.
5.2; Electrophoresis of Lipoproteins in Agarose
Gel s •
Lipoprotein preparations were routinely checked for 
contamination by other lipoproteins and plasma proteins 
by agarose gel electrophoresis (118). Preformed gels 
were employed in a commercial kit system (Corning Eel) . 
Protein and lipid bands were stained with Coomassie Blue 
(0.05% in 7.5% ethanoic acid) and Fat Red 7B (0 .023% in
absolute methanol) respectively.
This electrophoretic technique was also used 
to examine the relative electrophoretic mobilities of 
lipoproteins sampled from normal animals and those 
treated with drugs and to check the efficiency of the 
chemical modification of lipoproteins.
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5.3; Protein Assay.
The protein concentration in preparations of lipoproteins
was measured by the method of Lowry et al. (119) using 
human serum albumin (1.0 mg/ml) as a standard. ApoB 
concentration was measured using a modification of this 
method. The B apoprotein was first isolated by 
precipitation with an equal volume of pure, redistilled 
1 ,1 ,3,3,-tetramethylurea (TMU). Lipid in the precipitate 
was extracted by washing with 5 volumes of 
chloroform/methanol (2 : 1  v/v) followed by 5 volumes of 
diethyl ether. The pellet of apoB was dissolved in 
0.5 ml of 0.1 molar sodium hydroxide solution (120). This 
was then used to perform the Lowry assay.
5.4: Radiolabelling of Lipoproteins, Proteins and
Lipids.
5.4.1: The Iodine Monochloride Method
LDL was iodinated with either '■25i or ^31% (Radiochemical 
Centre, Amersham, UK) by the method of Macfarlane (121). 
Radioiodo-LDL prepared by this method has previously been 
characterised (122). The procedure introduces an atom of 
iodine into the phenolic ring structure of a tyrosine 
residue by electrophilic addition. Conditions være 
adjusted to limit iodination to one mole of iodine per 
mole of apoprotein, the mass of which was assumed to be
64,000 daltons for LDL and 100,000 daltons for VLDL.
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Sample Calculation:
cone, of lipoprotein apoprotein = 5 mg/ml
cone, of I d  solution = 3 5  nmoles/ml
Molecular weight of protein (LDL) = 64,000 daltons
ICI was used in a 2.5:1 molar ratio with protein.
no of nmoles of protein per ml of LDL solution = 
5.0x1x106/64,000 = 78.1 nmoli.es
no. of nmoles of ICI required = 78. 1x2.5 = 195.3 nmoles 
amount of ICI solution required = 195.3/25 = 7.8 pi.
Therefore to label 1.0 ml of 5 mg/ml LDL solution 
requires 1.0 mCi of radioiodide and 7.8 pi of 
25 nmoles/ml Iodine monochloride.
The product was purified by gel filtration 
through Sephadex G-25 (Pharmacia (GB) Ltd, London, UK) 
using buffer A as the eluant. Addition of an equal 
volume of 20% trichloroacetic acid (TCA) showed that 98% 
of the radioactivity was found in the precipitate. Lipid 
was shown to contain less than 5% of the radioactivity by 
solvent extraction with five volumes of chloroform/ 
methanol (2 : 1  v/v) and five volumes of diethyl ether.
The iodine monochloride method was also used 
to iodinate albumin and denatured albumin (assumed
molecular weight: 6 6 , 0 0 0  daltons).
The triglyceride triolein (Sigma Ltd, London, 
UK) was radioiodinated by a modification of the iodine 
monochloride method. 0.25 mCi of 125i „as added to 1.0 g 
of triolein and ICI added in a 1:1 molar ratio with the
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t r i o l e i n .  The reaction mixture was allowed to stand at 
room temperature for 5 minutes after thorough mixing then
washed repeatedly with 2 ml aliquots of buffer A. The 
buffer A was drained from beneath the oil layer until no 
r a d i o a c t i v i t y  was detectable. The purity of the product 
was determined by thin layer chromatography using 
heptane/ethyl acetate (9.1 v/v) as the solvent. The 
single band of product was observed under ultra-violet 
light. Radiolabelling was confirmed by scraping the band 
from the plate and counting in a, twin channel gamma 
counter (Packard Instruments, Dowers Grove, I L , USA). 
This machine was used routinely for the determination of 
the radioactivity of materials and samples.
5.4.2: Addition of Radiolabelled Cellobiose-Tyramine
to Lipoproteins and Albumin.
Cellobiose Tyramine (CT) (ref. 101) was labelled with 
125% and 131 j by a modification of the iodine 
monochloride method (123). A 5.0 -mmolar (2.4 mg/ml) 
solution of CT in water was prepared. 50 ul (250 nmoles) 
of this was mixed with 10 ul of 0,3 molar potassium 
dihydrogen phosphate (pH 4.5) and 1 mCi of ^25j or ^^^I, 
250 nmoles of iodine monochloride (25 nmoles/pl) was then 
added and the reaction allowed to proceed for 15 minutes 
at room temperature. After this time 500 ul of distilled 
w a t e r  was added and the lodo-CT purified anion
e x c h a n g e  on S e p h a d e x  QAE-A50 anion exchange resin 
(Pharmacia) using water as the eluant. The lodo CT was
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collected in 3 to 4 ml and lyophilised then redissolved 
in 50 pi of water.
lodo-CT was linked to the lysyl residue of a 
protein by a cyanuric chloride bridge (123). 1 0  ul of
the radiolabelled CT solution was mixed with 20 ul of 
cyanuric chloride dissolved in acetone (2 . 5  mg/ml 
acetone), 15 ul of 8 mmolar sodium hydroxide and 10 ul of 
water. This was allowed to stand at room temperature for 
15 seconds then 1 .0 ml of 5 mg/ml protein solution 
(buffer A, pH 8,1) was added rapidly. The reaction 
mixture was left at room temperature for 3 hours and the 
protein isolated by gel filtration through Sephadex G-25 
(Pharmacia) using buffer A (pH 8.1) as the eluant.
When used to label albumin this method 
yielded a product in which more than 95% of the radio­
activity precipitated in 10% TCA. When used to label 
lipoproteins less than 5% of radioactivity remained in 
the solution in 10% TCA and less than 2% of the radio­
activity was extracted with the lipid (section 5.4.1). 
Addition of iodo-CT to lipoproteins did not alter their 
metabolism (123).
5.5; Chemical Modification of Lipoproteins.
5.5.1; Reductive Méthylation
R e d u c t i v e  méthylation of lipoproteins was carried out by 
a modification (125) of the method of Means and Feeney 
(126) u s i n g  formaldehyde (methanol) and sodium borohy- 
dride (Sigma Chemicals Ltd). The lipoprotein solution
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(5 mg/ml) was cooled to 0“C in an ice bath. 0.5 ml of a 
freshly prepared 2 mg/ml solution of sodium borohydride 
in 0.2 molar borate buffer (pH 8.0) was added with 
constant stirring. 1 . 0 jjl of formaldehyde was added at 
five minute intervals for 30 minutes and the mixture left 
for a further 30 minutes at 0°C. Methylated LDL (MET- 
LDL) was purified by gel filtration through Sephadex G-25 
(Pharmacia) using buffer A as the eluant.
This procedure modifies the epsilon-amino 
group of lysine residues forming dimethyl lysine 
(Fig. 12). Other free amino groups such as the alpha-N- 
terminal group are presumably also modified. It has been 
reported (127) that this method modifies more than 75% of 
free amino groups.
Agarose gel electrophoresis of reductively 
methylated LDL revealed no change in the mobility of the 
lipoprotein relative to native LDL (Fig. 11) indicating 
that the net charge of the particle remained unchanged. 
This was due to the ability of the dimethyl epsilon amino 
group -N(CH 3 ) 2  to form the positive ion -N+(CH3 )2 H in a 
manner similar to that of the un-modified amino group.
5.5.2; Acétylation of Proteins.
Acétylation of albumin and lipoproteins was achieved by 
the reaction of acetic anhydride with lysyl residues 
(128) (Fig. 13). 1 . 0  ml of a 5 mg/ral solution of protein
or lipoprotein was diluted by the addition of an equal 
volume of saturated sodium acetate. This solution was
eORIGIN
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FIGURE 11: Agarose Gel Electrophoresis
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cooled to O'C in an ice bath and 1.0 ul of acetic
anhydride (Sigma Ltd) added at five minute intervals for
60 minutes with constant stirring. The reaction mixture
was left for a further 30 minutes at 0°C and the acety-
lated protein (Ac-LDL or Ac-BSA) purified by gel
filtration in Sephadex G-25 (Pharmacia) and dialysis in 
buffer A.
This procedure increases the net negative 
charge on the protein as shown by its enhanced anodic 
mobility in agarose gel electrophoresis (Fig. 14). This 
was due to the inability of the acetylated lysine residue 
(-NHCHOHCH 3 ) to form a positive ion.
5.6: Quantitation of LDL Apoprotein B.
LDL apoprotein B in rabbit plasma was measured by the 
immunoelectrophoretic method of Laurell (129). The 
electrophoresis was carried out on a one percent agarose 
slab gel formed on a glass slide. A two percent agarose 
preparation was melted and diluted with an equal volume 
of 0.1 molar barbitone buffer at pH 8 . 6  and antiserum 
raised to rabbit apoB in Guinea Pigs was added to a final 
concentration of two percent. Plasma was diluted 
1 : 1 0 ,000 with 0.05 molar barbitone buffer (pH 8 .6 ) and 
applied to wells cut in the cathode side of the gel. 
Following electrophoresis at 250 volts and 15 C for 16 
hours the plate was washed in saline for a minimum of 3 
hours to remove the serum proteins in the gel and stained 
with one percent amido black in ten percent acetic acid
+2. 3 4 ,Origin
Fig. 14; Agarose gel electrophoresis
Lane 1 Acetylated LDL
2 Acetylated LDL
3 Native LDL
4 Native LDL
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s o l u t i o n .  The plate was destained in methanol/acetic 
acid/water (50:10:40: v/v). The height of the peaks was 
m e a s u r e d  and compared to a standard of known apoB
concentration run on the same plate.
Quantitation of Plasma and Lipoprotein 
Cholesterol and Triglyceride.
Cholesterol and triglyceride were measured by standard 
methods (129) in either whole plasma or lipoprotein 
fractions using commercially available kits (Boehringer 
Corp. : Cholesterol Kit 236691 , Triglyceride Kit 166448). 
A standard cholesterol was obtained from BDH Ltd, and 
triglyceride (triolein) from Sigma Chemicals Ltd.
Cholesterol and triglyceride contents of 
lipoprotein fractions in plasma were obtained as follows: 
VLDL and LDL were precipitated with heparin/manganese 
chloride (130) leaving HDL in solution. The lipids in 
the total plasma were assayed and the lipid concentra­
tions in the HDL supernatant subtracted to give VLDL and 
LDL lipid values.
5.8: Conjugation of Muramyl Dipeptide to Acetyl­
ated BSA.
Muramyl dipeptide (MDP) (Fig- ISA) (kindly provided by 
Syntex Ltd, Palo Alto, California, DSA) was conjugated to 
albumin, which had previously been acetylated by the 
method outlined in section 5.5.3, through a c a r b o d i i . i d e  
link. 5.0 ml of 5 mg/ml acetylated albumin was dialysed
A:
N acetyl 
muromic acid
ChipH
HN Ac
f ig u r e  15;
Muramyl dipeptide
CH.CO.NH.CH.CO.NH.CH.CO.NH.
CH. CH 3
alanine
CH2CH2COOH
isoglutamine
B:
M D P
Muramyl dipeptide complexes
CO.NH.CH.CO.NH.CH2CH2O-  Phosphatidic acid 
CHo
Albumin - Ac
Muramyl Dipeptide and complexes.
Targeting to the reticuloendothelial system by incorporation 
via the Phosphatidic acid tail of MTP or conjugation to 
acetylated albumin.
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exhaustively against 0 . 1  molar phosphate buffered saline 
at pH 5.5 (Buffer B). 30.0 mg of 1-ethyl-3-(-3-dimethyl
aminopropyD-carbodiimide hydrochloride (Sigma Chemicals 
Ltd) was dissolved in 500 ul of buffer B and added to the 
Ac-BSA solution with constant stirring and left for 5 
seconds. This was followed by the addition of 20 mg of 
MDP also dissolved in 500 ul buffer B. The reaction 
mixture was covered and left at room temperature for 5  
hours. After this time it was dialysed against buffer A. 
The conjugate (Fig. 15B) was stored at -20“C in 1.0 ml 
aliquots to avoid continuous freezing and thawing. 
MDP-Ac-BSA was given to experimental animals intra­
venously at 1.39 mg of Ac-BSA/kg body weight (1.11 mg of 
MDP/kg body weight).
5.9; Preparation of Ethyl Oleate Emulsion.
Oleic acid ethyl ester (ethyl oleate) (Sigma Chemicals 
Ltd) was injected intravenously into experimental animals 
in the form of a stabilised emulsion in saline. 1 . 0  g of 
ethyl oleate was measured into a sterile glass tube. 
35 ul of Tween 20 detergent (Koch—Light Laboratories Ltd, 
Bucks, UK) was added with mixing, followed by 4 ml of 
sterile saline. This was then sonicated in an MSE 
P6.1199 sonicator for 5 minutes in an ice bath. The 
emulsion was prepared immediately before use and given in 
a dose of 0.5 g/kg body weight. Tween 20 detergent had 
previously been shown to have no effect on the animals in 
the amounts used in the preparation of the emulsion
(1 0 2).
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5.10: Preparation of MTP-Triolein Emulsions.
Muramyl tripeptide phospholipid (MTP) (Fig. 15b) is a 
derivative of NK)P (section 5.8) in which a phospholipid 
moiety is linked to the isoglutamine residue of MDP 
through a second alanine residue. This modification 
allowed the MTP to be incorporated into hydrophobic 
liposomes constructed from the triglyceride triolein 
(Sigma Chemicals Ltd).
0.25 g of triolein was added to 3 mg of MTP 
followed by 1.0 ml of saline. 9 jul of Tween 20 (Koch- 
Light Laboratories Ltd) was added and the mixture 
sonicated for 5 minutes in an ice bath. The emulsion was 
injected intravenously at the dose of 1 mg MTP/kg body 
weight immediately after preparation.
5.11: Dénaturation of Albumin.
Albumin was dissolved in 0.05M bicarbonate buffered 
saline at pH 10.0 (Buffer C) to a concentration of 
1 0  mg/ml. 1 . 0  ml of this solution was diluted to 1 0  ml 
with a 4.4% formaldehyde solution in buffer C yielding a 
final solution of 1 mg/ml albumin and 4 percent form­
aldehyde in buffer C. This was left at 4 C for 3 days
then dialysed exhaustively against buffer A.
Agarose gel electrophoresis (section 5.2) 
revealed that the albumin treated in this way had a 
greater overall negative charge than native albumin 
(Fig. 16). The formaldehyde denatured albumin was shown
f ig u r e  16;
0
ORIG IN
LANE 1. Native albumin
2. Native albumin
3. Formaldehyde denatured albumin
4. Formaldehyde denatured albumin
Agarose gel electrophoresis:
Comparison of the mobilities of native 
and formaldehyde denatured albumin.
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to be an ideal marker of In vitro macrophage activity, 
being rapidly degraded by cultures of the cells.
5.12: Measurement of Macrophage System Activity
In Vivo.
Macrophage system function was measured in vivo using 
intravenously injected colloidal carbon ( 1 0 0  mg/kg body 
weight) by standard methods (131). After injection the 
concentration of colloidal carbon in the plasma was 
measured in serial blood samples taken over a period of 
30-60 minutes by light transmission at 700 nm. The 
phagocytic index K, defined as the slope of the graph
plotted as logarithm of optical density of the plasma at
700 nm versus time, was determined for the animal in the 
control state and after it had received macrophage system 
modulating agents. To ensure that the colloidal carbon 
was not eliciting any effects, K was redetermined two 
weeks after treatment of the animal with the drugs and 
compared to K calculated for the animal in the control 
state.
5.13: Cell Cultures.
5.13.1: Human Skin Fibroblasts.
Normal h u m a n  skin fibroblasts were obtained from Flow 
Laboratories (Irvine, Scotland, UK). The cells were 
maintained at 37°C in an atmosphere of 5% CO2 and 95% air 
in Basal Eagles Medium (BEM) (Flow Laboratories). The
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BEM was supplemented with 10% new born calf serum,
2 mmolar glutamine, 1 % non-essential amino acids (all 
from Flow Laboratories), 1 . 6 8  g/l sodium hydrogen
carbonate, 1 0 0  units/ml penicillin and 1 0 0  mg/ml strepto­
mycin. This complete medium was denoted medium A. The 
cultures were grown in Nuclon- 50 ml plastic flasks (Gibco 
Biocult, Ltd, Paisley, Scotland, UK) and passaged into 
fresh medium A when confluent by dissociation with 0.5% 
trypsin/0.02% disodium EDTA (Gibco Biocult Ltd).
5.13.2: Macrophages.
Peritoneal macrophages were harvested from mice using 
standard techniques (132). The animals were killed in 
ether and the skin over the abdomen removed. Ten 
millilitres of phosphate buffered saline at pH 7.4 was 
injected rapidly into the peritoneal cavity through a 
large gauge needle. The needle was oriented so that the 
bevel faced down and the abdominal wall was elevated to 
form a tent structure. The fluid, containing the cells, 
was withdrawn slowly by sterile syringe and transferred 
to centrifuge tubes. It was centrifuged at 150 g for 8  
minutes and resuspended in medium A. After five hours 
incubation at 37 °C the medium was replaced by fresh 
medium A to ensure minimum contamination by other cell 
types.
A transformed line of mouse macrophages 
(J774A) (133) was obtained as a gift from Dr David Hart,
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Department of Zoology, University of Glasgow, UK. These 
cells were maintained in medium A.
5.13.3; Cryogenic Storage of Cell Lines.
Both fibroblasts and macrophages were stored long term in 
liquid nitrogen (Cryoservice Ltd, Hamilton, Scotland) . 
The cells were dissociated from the growth flasks just 
before reaching confluence and centrifuged at 150 g for 8  
minutes at 20 C. They were resuspended in new born calf 
serum containing 10% dimethyl sulphoxide (DMSO) (5 ml per 
flask of cells) and placed, in 1 . 0  ml batches, in sterile 
ampoules suitable for storage in liquid nitrogen (Gibco 
Biocult Ltd). The ampoules were sealed, placed in an 
insulated container and cooled slowly (1*C/minute) to a 
temperature of -60 “C. They were then transferred to a 
liquid nitrogen freezer and kept in the liquid phase.
Thawing was carried out rapidly in warm water 
(40*0 and the liquid immediately poured into 1 0  ml of 
medium A (per ampoule). This was centrifuged at 150 g 
for 8 minutes and the cells resuspended in 5 ml of medium 
A. The cells were placed in a growing flask and incubated 
at 3 7  *c for 24 hours at which time the medium was 
replaced to remove any dead cells which may have been
present.
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5.14; Binding and Degradation of Lipoprotein
In Vivo.
5.14.1; In Vitro Receptor Assay.
All assays of receptor activity in cultured cells were 
carried out after incubation for 48-72 hours, prior to 
the assay, in medium B. Medium B was identical to medium 
A except that it contained lipoprotein deficient serum 
(LDS) instead of complete serum. LDS was prepared from 
fresh human serum by ultracentrifugal flotation through a 
solution of density 1.25 kg/1 at 45,000 rpm and 15*c for 
48 hours using a Beckman Ti60 rotor in an L565 ultra­
centrifuge (133).
Excess salt was removed by exhaustive 
dialysis against buffer A at pH 7.0 and the protein 
content was adjusted to 50 mg/ml. The final preparation 
was sterilised by membrane filtration through 0.45 u and 
0.22 u filters in series (Millipore Corp, Bedford, MA, 
US).
Incubation of fibroblasts for 48-72 hours in 
medium B has been shown to stimulate LDL receptor 
activity (135).
5.14.2; Measurement of Receptor Binding.
Goldstein et al. (91) described the procedure for the 
measurement of lipoprotein binding to the LDL receptor. 
It was found, however, that, especially with macrophages, 
the cell tended to dissociate from the wall of the
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culture flask if incubated at 4°C. A modification of the 
method whereby cells were incubated at room temperature 
was employed to overcome this problem.
Cultures were equilibrated at room tempera­
ture for 30 minutes after an incubation of 48-72 hours at 
37 C in medium B. After this equilibration period, 
medium B was removed from the cultures and replaced with 
medium B containing 100 pg/ml of radioiodinated lipo­
protein at room temperature. This was left for a further 
two hours at room temperature, the medium removed and the 
cells washed six times with 5 ml aliquots of 0.1 molar 
phosphate buffered saline at pH 7.4 containing 2 mg/ml 
BSA. The monolayer of cells was then dissolved in 2.0 ml 
of 0 . 1  molar sodium hydroxide which was aliquoted for 
determination of radioactivity and protein.
5,14.3: Measurement of Lipoprotein Degradation.
Lipoprotein degradation in tissue culture was quantified 
by the measurement of the amount of. radioactivity which 
was not precipitated by trichloroacetic acid (TCA) or 
extracted as iodine into chloroform ie that present as 
iodotyrosine, the radioactive break-down product of the
protein moiety.
After incubation of 37°C with medium B for
48-72 hours medium B containing 100 to 200 pg/ml
( 1x106 cpm/ml) of radioactive lipoprotein was added to
the cultures. TCA was added to the culture tubes to a
final concentration of 25% at selected time intervals up
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to 8 hours. The precipitate was removed by low speed 
centrifugation and the supernatant supplemented with 
non-radioactive potassium iodide, to a final concentra- 
tion of 0.4%, to act as a carrier for radioactive iodide. 
This was oxidised to iodine by the addition of 1 part 
hydrogen peroxide (30 volume) to 10 parts supernatant 
and extracted into twice the volume of chloroform. The 
aqueous layer was then removed and the radioactivity 
present as 125i or T31%-tyrosine determined. Protein 
content of the culture tubes was measured in duplicate 
control cultures which received only medium B with the 
same amount of unlabelled lipoprotein.
5.14.4: Treatment of Cell Cultures with MDP-Ac-BSA.
Cultures received MDP-Ac-BSA 18 hours before the start of 
the experiment. The drug was delivered in medium C which 
was identical to medium B except that it contained two 
percent LDS and 0 to 500 pg/ml as measured for protein 
(0-400 pg MDP) MDP-Ac-BSA. In preliminary experiments 
medium C contained no LDS to prevent degradation of 
MD-Ac-BSA but it was found that control cultures failed 
to thrive in this medium. Further experimentation showed 
that for periods of 24-48 hours medium C supplemented 
with 2% LDS provided a suitable medium for growth. 
Control cultures for these experiments received medium C 
containing no MDP-Ac-BSA for the same time as their 
experimental counterparts.
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5.15: Animals and Diets.
5.15.1 : New Zealand White Rabbits.
All studies undertaken in rabbits were carried out using 
male New Zealand White Rabbits (Cheshire Rabbit Farms, 
Cheshire, UK) at the age of 4-6 months (3-3.5 kg weight). 
These animals were maintained on a standard rabbit diet 
(B Special Diet Services, Witha, Essex, UK) ad libitum, 
unless otherwise indicated.
5.15.2: Dunkin-Hartley Guinea Pigs.
Antibodies to rabbit apoB were raised in the Dunkin-H­
artley strain of Guinea Pigs (Bantin and Kingman, Hull, 
UK). The animals were maintained on Guinea Pig 
Maintenance Diet (BP Special Diet Services) supplemented 
with hay (Finest Meadow Hay, Darleith Farm, Cardross, 
Scotland).
5.15.3: BALB/C Mice.
All mice used were of the BALB/C strain. They were 
maintained on Rat and Mouse Maintenance Diet (BP Special 
Diet Services) ad libitum. The mice were bred in the 
animal unit under the expert eye of Mr Stuart Saigeman,
5.16: Protocol for In Vivo Turnover Studies.
5.16.1: Injection and Blood Sampling.
Before any injection of radioiodolipoproteins the rabbits 
were given potassium iodide in the drinking water
60
(0 . 1  g/l), two days prior to and throughout each study, 
to prevent uptake of the radioiodine by the thyroid.
Lipoproteins, isolated from fresh plasma 
within 48 hours, were labelled with 125i or 131% (section
5.4.1), sterilised by ultrafiltration and injected into 
the marginal ear vein (10 pCi of ^25j^ approximately 
1x107cpm:18 pCi of ^31 j^ approximately IxlO^cpm with a 
total of 400 pg of protein).
Blood samples were taken, using disodium EDTA 
as the anticoagulant, from the marginal vein of the other 
ear at 1 0  minutes from injection and subsequently at 
regular intervals over the next 47 hours. The ten minute 
sample provided an estimate of plasma volume and the zero 
time point. Radioactivity in each sample was determined 
in a twin channel gamma spectrometer (Packard Instru­
ments). Plasma decay curves were calculated as a 
percentage of the 1 0  minute sample and plotted against 
time on three cycle semi—log graph paper. No reisolation 
of LDL from the plasma was necessary since non-protein 
bound radioactivity in the plasma was less than one 
percent of the total and apoB does not transfer to other 
lipoproteins (136) (Fig. 10).
15.16.2: Measurement of Tissue Uptake of Radiolabelled
Lipoproteins.
The tissue distribution of each isotope was measured 
immediately after the final blood sample was taken. In 
the case of 125; or 1311 labelled lipoproteins this
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occurred 36-48 hours after injection; in the case of 
125 i _ c t  and 131l-CT labelled lipoproteins at 48-60 hours 
after injection. The rabbits were anaesthetised with an 
injection of pentabarbitone sodium (30 mg/kg) (Sagital: 
May and Baker Ltd, Dagenham, UK) followed by an intra­
venous injection of 500 units/kg of sodium heparin 
(VîGddel Pharmaceuticals Ltd, London, UK) to prevent 
i^travascular coagulation, Exanguination was performed 5  
minutes later by cardiac puncture which removed more than 
80% of the total blood volume. The organs were dissected 
out, washed in ice-cold 0,15 molar sodium chloride 
solution, blotted dry and weighed. Samples of fat, gut 
and muscle were removed, cleaned and dried.
Accurately weighed, approximately one gram 
pieces of tissue were taken in quadruplicate and the 
amount of radioactivity present in each determined. This 
was corrected to give the amount of radioactivity present 
per gram of tissue and expressed relative to the radio­
activity measured in 1 . 0  ml of plasma at the time of 
sacrifice. The results were plotted as a bar graph 
showing {cpm/g tissue )/( cpm/ml plasma) for each tissue. 
Total organ uptake was calculated and plotted as above
for each weighed organ.
In previous studies each tissue sample was
homogenised, precipitated with TCA (final concentration 
1 0 %) and radioactivity determined in the washed pellet. 
This should reflect the tissue content of intact or high 
molecular weight break down products of LDL. Since at
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least 70-90% of radioactivity in the tissue was pre­
cipitated and these portions were unaffected by 
modification of the lipoprotein or by diet, the tissue 
radioactivities were measured directly.
Tissue uptake of 125%_CT and labelled
lipoproteins were determined in the manner outlined 
above.
5.16.3; Reisolation of LDL.
Radiolabelled LDL (section 5.4.1) was screened in vivo by 
injecting the lipoprotein into a rabbit. Each isotope 
( ie 125j and  ^31 % ) was injected into a separate animal. 
The plasma decay of the lipoprotein was followed (section
5.16.1) until the level of radioactivity was approximate­
ly ten percent of the initial ten minute sample. The 
rabbits were then anaesthetised with an injection of 
sodium pentabarbitone (30 mg/kg) (May and Baker Ltd), 
given an intravenous injection of 500 units/kg of sodium 
heparin (Weddel Pharmaceuticals Ltd) and exanguinated by 
cardiac puncture. VLDL was removed from the plasma by 
the method given in section 5.1.2(1). The density of the 
plasma was adjusted to 1.063 kg/1 with sodium bromide and 
overlayered with density 1 .063 kg/1 sodium bromide 
solution. This was centrifuged in a Beckman Ti60 rotor 
using an L565 ultracentrifuge for 24 hours at 49 ,000 rpm 
and 18*C. The LDL was dialysed against buffer A to
remove excess salt.
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Due to the loss of approximately 90% of the 
radioactivity the initial injection contained between
5 x 1 Q 7 and IxlO^ cpm and 500 ug of protein. This was 
achieved by increasing the specific activity of the 
lipoprotein in die labelling stage. The amount of iodine 
monochloride used was increased 1 , 5  fold as was the 
number of mCi of radioiodine.
^ ^7 : Separation of LDL Subfractions by Continuous
Gradient Ultracentrifugation.
LDL from normal rabbits and rabbits treated with ethyl 
oleate (section 5.9) was isolated by the following
method. Plasma from the rabbits was adjusted to a
density of 1.019 kg/1 by the addition of sodium bromide
and over layered with an equal volume of 1,019 kg/1
density solution in a Beckman Ti60 rotor. This was 
subjected to ultracentrifugation in a Beckman L5 65 
ultracentrifuge at 45 ,000 rpm and 18*C for 18 hours. The 
VLDL and IDL were removed, the infranatant adjusted to
1.070 kg / 1  with sodium bromide, overlayered with
1.070 kg / 1  density solution and subjected to ultra- 
centrifugation as described above. The supernatant LDL 
was removed and washed in a pressure ultrafiltration unit 
(amicon) using 1,040 kg/1 density solution until the 
washings had a refractive index of 1 ,3402, equivalent to 
a density of 1 ,040 kg/1 for sodium bromide solution. The 
LDL was then labelled by the ICI method (section 5,4,1)
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and exhaustively dialysed against a 1.040 kg/ 1  density 
solution containing 0.03% disodium EDTA at pH 7.4.
A Beckman SW40 rotor was prepared with a 
stepped gradient running from 1.060 kg/ 1  to 1 . 0 1 0  kg/ 1  in 
0.010 kg/1 increments (Fig. 17A), the sample, at 
1.040 kg/1, being placed in the centre of the tube. After 
18 or 24 hours ultracentrifugation at 39,000 rpm and 19°C 
in a Beckman L565 ultracentrifuge this step wise gradient 
formed a continuous gradient, as measured by refractive 
index (Fig. 17B). Aliquots of 0.5 ml were removed from 
the top of the gradient and the amount of radioactivity 
present in each determined.
5.18: Separation of LDL Subfractions by Anion
Exchange Column Chromatography.
DEAE Sepharose Anion Exchange Resin (CL6 B; Pharmacia Fine 
Chemicals AB, Uppsala, Sweden) was poured to a depth of 
8.5 cm in a 1 cm internal diameter column (Pharmacia Finô- 
Cheraical A B ) . This was topped with 2 cm of Sephadex 
Coarse G-25 (Pharmacia Fine Chemicals AB) and equili­
brated for 24 hours with 0.025 M tris buffer at pH 8.0. 
One millilitre of 0.5 mg/ml LDL in 0.025 M tris buffer at 
pH 8.0 was layered onto the column and washed in with
10 ml of tris buffer at pH 8.0.
The gradient of increasing sodium chloride
concentration was created by a gradient mixer (Pharmacia 
Fine Chemicals AB, model GM-1) and pumped onto the column 
at 0.4 ml/minute by a peristaltic pump (LKB Broma
f i g u r e  17: DENSITY<kg/l> VOLUME <ml>
10
J-182
2
2
2
2
2
2
0 5
DENSITY <kg/|> 
106
105
1044
103
102
2 4 6 8 10 12 14 16 18 20 22 24
FRACTION NUMBER
A: Stepwise gradient used to separate species of LDL by
density. The radiolabelled LDL was adjusted to d = 1.040 
and layered into the gradient.
B: Result of ultracentrifugation of stepwise gradient.
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Multiperpex Peristaltic Pump), Eluant was examined for 
protein content by ultra violet spectrophotometry (ISCO 
type 6 optical unit) which was recorded on a potentio- 
metric chart recorder. The conductivities of the 
fractions collected were determined by conductivity meter 
(Radiometer, Copenhagen, type CDM 2f) and plotted onto 
the chart recorder trace.
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6 : RESULTS
j^rget specialty of drug delivery vehicles.
6.1.1.: Lipid Vesicles.
^I“l^L)elled glycerol trioleate ( ^ —triolein ) vesicles
were injected into the marginal ear vein of New Zealand 
white rabbits (NZW rabbits). The plasma clearance rate 
was determined by serial blood sampling over a 30 minute 
period (Fig. R1) and expressed as the percent of the zero 
time radioactivity which remained in the plasma at time 
of sampling. The zero time radioactivity was calculated 
from the total amount of radioactivity injected and the 
plasma volume of the animal. After 30 minutes the animal 
was anaesthetised, exsanguinated and the tissue uptake of 
radioactivity determined. Tissue uptake was expressed in 
two forms; first the relative uptake per gram of tissue 
(Fig. R 2 ) and second the total uptake by the discrete 
organ (Fig. R3 ) . Although relative uptake per gram 
revealed that the spleen was extremely active, total 
organ uptake showed that liver, due to its size and 
activity, was responsible for the removal of the majority 
of 125j_triolein vesicles (39% of the injected dose).
6 12.: Acetylated Bovine Serum Albumin (Ac-BSA).
A c - B S A  was labelled with 125iod.ine and treated with 
carbodiiraide under the same conditions used for the 
conjugation of Huramyl Dipeptide (MDP) (section 5.8).
Zage
injected
dose
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TIM E (hours)
FIGURE R.l: Plasma Clearance of
Vesicles.
125
I-Triolein
Radioiodinated triolein vesicles 
were injected into the marginal ear 
vein of rabbits and the plasma 
clearance rate determined (n = 2 ).
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FIGURE R2; Relative T i s s u e  Uptake of ^^^I-Triolein Vesicles.
Relative tissue uptake of ^^^I-triolein into the tissues 
of NZW rabbits was determined 30 minutes after injection 
of the tracer.
,, a. cpm/qram of tissue
Relative Tissue Upt " cpm/ml of plasma
(n ■ 2)
Contractions;- LIV, liver; LNG, lung; PLA, plasma;
KID, kidney; HRT, heart; ADR, adrenal; 
FAT, fat; THY, thymus; GON, gonads;
MUS, muscle; SPL, spleen; AORTA, aorta.
The aorta was divided into two sections corresponding 
to first, the arch and upper thoracic regions and second 
thé lower thoracic and upper abdominal regions.
T h e s e  c o n t r a c t i o n s  will c o n t i n u e  to b e  u s e d  u n l e s s  
o t h e r w i s e  st a t e d .
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FIGURE R3: Total Organ Uptake of I-Triolein Vesicles.
Total organ uptake was calculated from cpm/gram of tissue.
cpm/gram of tissue x organ weight 
Total Organ Uptake - cpm in injected dose
(n = 2)
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This was then injected into the marginal ear vein of NZW 
rabbits. Thirty minutes after administration the rabbits 
were anaesthetised, exsanguinated and the tissue uptake 
of radiolabelled tracer determined. The tissue uptakes 
were expressed as described above (section 6 . 1 . 1 .). 
Relative uptake per gram of tissue showed that the liver 
was as active in the uptake of Ac-BSA as triolein 
vesicles (Fig. R 4 ) , but that the spleen, although the 
second most active tissue, was less than 1 0 % as efficient 
in catabolism of Ac-BSA. Whole organ uptake (Fig. R5 ) 
revealed that the liver, as with triolein vesicles, 
removed 40% of the tracer, although approximately twice 
as much remained in the plasma after 30 minutes.
It is important to note that the amount of 
radioactivity found in the tissues was that at the 
instant of death and was not cumulative, ie did not 
include low molecular weight catabolic products which 
were excreted back into the plasma and removed by the 
kidney. However, the figures quoted gave realistic 
representations of relative uptakes by the tissues.
6.2.: Effects of reticuloendothelial system sup­
pressants on plasma lipids.
6.2.1.: Ethyl oleate emulsion.
NZW rabbits received three serial injections of ethyl 
oleate emulsion (0 . 5  g ethyl oleate/kg body weight) at 
48 hour intervals to produce sustained suppression of 
reticuloendothelial (RE) activity (Fig. R 6 ) . Following
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FIGURE R5
125
Total Organ Uptake of I-Ac-BSA
This was calculated from the number of counts per minute in 
one gram of tissue and expressed as a percentage of total 
injected dose.
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FIGURE R 6 : Plasma Lipids in NZW Rabbits Treated with Ethyl Oleate
The animals were given intravenous injection of ethyl 
oleate emulsion at the times indicated by the arrows 
(t ) and cholesterol and triglyceride contents of the 
plasma lipoproteins determined.
o total cholesterol (mmol/1 )
• LDL cholesterol (mmol/1)
A HDL cholesterol (mmol/1)
▲ VLDL cholesterol (mmol/1)
■ total triglyceride (mmol/1 )
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each injection there was a rapid but transient increase
in plasma triglyceride levels. This hypertriglycerid- 
aemia resolved within 48 hours and by the end of the 
study had returned to the base-line value. Total plasma 
cholesterol concentration increased and, failing to 
resolve between ethyl oleate injections, reached a value 
twice that of the control after the third injection. This 
increase was due to a specific increment in LDL chol­
esterol, since HDL cholesterol was not affected and VLDL 
cholesterol increased only slightly (Fig. R 6 ). This 
experiment was repeated in a second group of animals 
which received intravenous ethyl oleate emulsion at 
24 hour intervals instead of 48 hour intervals (Fig. R7). 
Again triglyceride levels increased rapidly and resolved 
between injections. HDL cholesterol remained constant 
over the period of the study and VLDL cholesterol 
increased only slightly. Total plasma cholesterol 
increased reaching a peak of 2.5 times control value 
after the fourth injection. The increase in total 
cholesterol, again, was reflected by an increase in the
LDL cholesterol component (Fig. R7 ) .
The mean values for total plasma cholesterol 
and triglyceride for all the animals in this group were 
calculated (Figures R 8 and R9 respectively). Total 
cholesterol rose, reaching a new steady state by the 
fourth day at which time the value was significantly 
different from control values at the 5% level. Tri- 
glyceride, however, reached a peak 1 2  to 24 hours after
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FIGURE R7: Plasma Lipids in NZW Rabbits Treated with Ethyl Oleate.
The animals were given intravenous injections of ethyl 
oleate emulsion at 24 hour intervals (T ) and the plasma 
cholesterol and triglyceride levels determined (mmol/1).
O total cholesterol 
# LDL cholesterol 
A  HDL cholesterol 
▲  VLDL cholesterol 
■ total triglyceride
NB: The scalar for cholesterol is the same for triglyceride
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FIGURE R8; Total Plasma Cholesterol in NZW Rabbits Treated with Ethyl Oleate.
The animals were given intravenous injections of ethyl oleate 
emulstion (T) and the plasma cholesterol levels determined.
unpaired t-test control vs 4th day p <0.05 (n = 3)
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FIGURE R9: Total Plasma Triglyceride Concentration in NZW Rabbits Treated
with Ethyl Oleate.
The animals were given intravenous injections of ethyl oleate 
emulsion (f ) and plasma triglyceride determined.
unpaired t-test control vs 4th day p<0.5 (n = 3)
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the first injection and from then resolved to the 
base-line value by the fourth day.
Muramyl Tripeptide in Triolein Vesicles (MTP- 
Triolein).
NZW rabbits received one injection of MTP-triolein (1 mg 
MTP/kg body weight in a total of 0.25 g of triolein). 
This single injection produced a marked rise in LDL 
cholesterol (Fig. RIO) which peaked at approximately 
30 hours (2.5 times control value) and required a further 
42 hours to resolve. HDL cholesterol was unaffected by 
the manoeuvre but total triglyceride increased dramatic­
ally resolving within 30 hours (not shown).
6.2.3.: Muramyl Dipeptide Conjugated to Acetylated 
BSA (MDP-Ac-BSA).
The rabbits were given one intravenous injection of 
1.1 mg MDP per kg body weight (Fig. R11). The pattern of 
change in lipid levels were similar but not as pronounced 
as those affected with MTP-triolein. Triglyceride rose 
rapidly but did not resolve as quickly. The rise in 
total cholesterol was reflected by an increase in LDL 
cholesterol and, although VLDL cholesterol increased 
more, HDL cholesterol remained unchanged.
6.2.4.: Ethyl Oleate and Cholesterol Feeding.
Ten rabbits were fed with normal rabbit.chow which was
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FIGURE RIO: Plasma Lipoprotein Cholesterol Levels in NZW Rabbits Treated
with Muramyl Tripeptide in Triolein Vesicles (MTP-Triolein).
The animals were injected intravenously (T ) with MTP-triolein 
(1 mg MTP/kg body weight) and LDL ( •) and HDL {A) cholesterol 
levels in the plasma measured.
unpaired t-test control vs peak LDL cholesterol level 
p <0.02 (n = 3).
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supplemented with 1% (w/w) cholesterol. Five of the 
rabbits, group 2 , received only this diet and five, group 
1 , received the diet and were treated with twice-weekly 
injections of ethyl oleate emulsion (0 . 5  g ethyl oleate 
per kg body weight). The animals were maintained on this 
regimen for 40 days, blood samples for the determination 
of total cholesterol and triglyceride concentrations 
being removed twice-weekly. Cholesterol levels increased 
dramatically reaching as high as 60 mmol 1"1 (Fig. R12) 
but no significant difference was observed between the 
mean values for groups 1 and 2. Trig]yceride levels 
increased to a much lesser extent (Fig. R13 ) but, again, 
there was no significant difference in the mean values, 
despite the apparently higher mean level measured in 
group 1 .
6.2.5.: Ethyl Oleate and Starvation.
Six rabbits were divided into two groups of 3 animals 
each. Group 1 was given four daily, injections of ethyl 
oleate emulsion and deprived of food during this period. 
Group 2 was starved for four days. Serial blood samples 
were withdrawn for the determination of plasma lipid 
levels. The animals which received ethyl oleate (Fig. R14 
panels A and C) showed a rapid but transient increase in 
triglyceride levels which resolved within 48 hours and a 
rapid but stable increase in cholesterol levels, 
typically rising 5 fold over control values. Animals in 
group 2 (Fig. R14 panels B and D) showed a slight
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FIGURE R12: Effect of Cholesterol Feeding and Ethyl Oleate on the
Plasma Cholesterol Levels in NZW Rabbits.
The animals were fed a diet containing 1% (w/w) cholesterol 
Group 1 also received an intravenous injection of ethyl 
oleate emulsion twice per week. The cholesterol levels 
in the plasma of the animals in both groups were 
measured.
•: group 1; cholesterol feeding plus ethyl oleate
A: group 2; cholesterol feeding only.
unpaired t-test.
control vs end point (group 1) p <0.001 (n = 5)
control vs end point (group 2) p <0.001 (n = 5)
end point group 1 vs endpoint group 2 p >0.5 (n = 5:
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FIGURE R13: Effect of Cholesterol Feeding and Ethyl Oleate
on the Plasma Triglyceride Levels in NZW 
Rabbits.
The animals were fed a diet containing 1% (w/w) 
cholesterol. Group 1 also received an 
intravenous injection of ethyl oleate emulsion 
twice per week. The triglyceride levels in 
the plasma of the animals in both groups were 
measured.
#: Group 1; cholesterol feeding plus ethyl
oleate (n = 5).
A: Group 2; cholesterol feeding only (n = 5) .
unpaired t-test
control vs end point (Group 1) p < 0.001
control vs end point (Group 2) p < 0.01
end point group 1 vs end point group 2 p = 0.05
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FIGURE RI4:
TIM E days
Effect of Starvation and Ethyl Oleate on the Plasma 
Cholesterol and Triglyceride Levels in NZW Rabbits.
The animals were starved for four days, during which time 
Group 1 received intravenous ethyl oleate emulsion at 
24 hour intervals. The plasma cholesterol and triglyceride 
levels were determined from blood samples removed immediately 
before the ethyl oleate injections.
- Cholesterol levels in Group 1 (starved + ethyl oleate)
- Cholesterol levels in Group 2 (starved only)
- Triglyceride levels in Group 1 (starved + ethyl oleate)
- Triglyceride levels in Group 2 (starved only)
A Rabbit 1 
• Rabbit 2 
■ Rabbit 3
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increase in cholesterol concentration and a small fall in 
triglyceride levels.
Total plasma fatty acid concentrations in 
groups 1 and 2 were also measured. Group 1, receiving 
ethyl oleate, showed a two fold increase in stearate 
(cl 6:0) (Fig. R15) from 350 pg/ml to 700 pg/ml whereas the 
concentration of oleate (c18:1) almost halved (400 pg/ml 
to 220 pg/ml ) . This observation was significant because 
animals in this group received a total of 6 grams of 
ethyl oleate each over a 4 day period. In' the control 
group stearate increased to a peak at 2 days, returning 
to control values by day 4. Oleate showed a similar but 
less pronounced pattern, rising to a peak and returning 
to base-line values in 4 days (Fig. R15).
6.3.: Effects of Reticuloendothelial System
Suppressants on Phagocytic Function, as 
Measured by the Rate of Carbon Particle
Clearance In Vivo.
6.3.1.: Ethyl Oleate Emulsion.
Clearance of particulate matter, such as colloidal 
carbon, from the plasma is a function of the macrophages 
of the RE system. To ensure that ethyl oleate, and other 
such agents, elicit their effects through the suppression 
of that system the Phagocytic Index, K, was determined. K 
was calculated as follows:
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FIGURE R15: Effect of starvation and ethyl oleate treatment
on the fatty acid concentrations in rabbit 
plasma.
# Ethyl oleate + starvation on cl6:0 
▲ Starvation only on cl6:0 
O Ethyl oleate + starvation on cl8:l 
A  Starvation only on cl8:l
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logio OD700 ^2 “ I0910 OD700 Pi 
K =  ---------------------------------
t2 - ti
where K = Phagocytic Index
OD 7 0 0  = optical density of the plasma at 700mm
? 2  = second selected point
= first selected point 
t^ = time, in hours, of P^
t^  = time, in hours, of P^
K then was determined for animals in the control state 
and then after 4 daily injections of ethyl oleate 
emulsion (Fig. R16). These measurements were carried out 
two weeks apart to ensure that the phagocytosed carbon
particles did not themselves exert an inhibitory effect. 
Under the influence of ethyl oleate, K increased from 
-1.08 hours-1 to -0.57 hours“ 1 (Fig. R16) thus 
demonstrating an inhibitory effect on the RE system.
6.3.2.: Muramyl Tripeptide in Triolein Vesicles (MTP-
triolein ) .
The experiment described in section 6.3.1. was repeated 
in 3 rabbits receiving one injection of MTP-triolein 
(1 mg MTP per kg body weight) instead of the ethyl 
oleate. K was determined in the control state then 24 
hours after administration of MTP-triolein (Fig. R17) 
Again, two weeks was allowed for recovery from the 
colloidal carbon administered for the measurement of 
control K.
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Phagocytic index in the control state was 
- 1 . 2 0  ± 0,30 hours"! which compared favourably with
control K in section 6.3,1. This increased to -0.20 ± 
0.19 hours"! after treatment with MTP-triolein which 
represented a significant increase (p<0 .0 2 ) over the 
control value (Table R 1 ). Thus a single injection of 
MTP-triolein significantly increased the time required to 
clear particulate matter from the plasma of animals, 
demonstrating an inhibition of the RE system.
In this experiment K was redetermined two 
weeks after the MTP-triolein had been given in two of the 
rabbits. K had decreased from -0.20 hours"! 24 hours 
after MTP-triolein to -1.63 hours"! two weeks later
which, although not identical with the initial value, 
showed that, if an interval of two weeks was left between 
consecutive measurements of phagocytic index, no 
inhibitory effect persisted due to the colloidal carbon. 
Figure R18 shows the effect of both ethyl oleate and 
MTP-triolein on the value of K.
6.4 : Effect of Reticuloendothelial Suppression on
the Degradation of Denatured Albumin by 
Macrophages In Vitro.
6.4.1.: Muramyl Dipeptide (MDP) and Muramyl Tri­
peptide (MTP) in Free Solution.
J774 mouse macrophages were exposed to 250 MDP/ml or 
250 pg MTP/ml for 18 hours. At the end of this period 
the cells were tested for their ability to degrade
^ --- RABBIT
1 2 3 Mean
^ CONTROL -1.39 -1.35 -0.55 -1.20 + 0.30
^ MTP -0.23 -0.38 0.00 -0.20 + 0.19
AFTER -1.79 -1.46 ND -1.63
TABLE RI: Effects of MTP-Triolein on the Clearance of
Colloidal Carbon in NZW Rabbits.
a : unpaired t-test control vs MTP triolein 
treated animals P <0.02.
Values for Phagocytic Index (K) in NZW rabbits 
in the control state (CONTROL), 24 hours after 
treatment with MTP-triolein (MTP) and two weeks 
after treatment with MTP-triolein (AFTER).
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FIGURE R18; Effect of Ethyl Oleate and MTP-Triolein on 
the Phagocytic Index in NZW Rabbits.
A: Control Animals 
B: MTP-Triolein Treated Rabbits 
C: Ethyl Oleate Treated Rabbits 
D: 2 weeks after treatment.
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formaldehyde denatured albumin compared to cells which 
had received no treatment (Fig. R19), Degradation of the 
marker v;as measured as the amount of radioactivity 
present as 125%_tyrosine (section 5.14,3.) per ug of cell 
protein in the assay tube. Cells which had been 
incubated with MDP catabolised only 12.7% as much as the 
control cells and those incubated with MTP only 3.2% as 
much. This in vitro suppression of the ability of 
macrophages to degrade the marker supported the results 
obtained in vivo (section 6.3).
6.4.2.: Muramyl Tripeptide in Triolein Vesicles (MTP-
triolein ) .
J774 mouse macrophages were exposed to MTP-triolein or to 
triolein vesicles for 18 hours. At the end of this 
incubation the cells were challenged with denatured 
albumin and their ability to degrade the marker determin­
ed as above (Fig. R20 ) . Cells which had been incubated 
with MTP-triolein catabolised only 3.9% as much marker as 
control cells. Those which received triolein vesicles 
only were not significantly suppressed in their ability 
to degrade denatured albumin.
Again MTP-triolein incubation supported the 
results obtained in vivo and exposure to triolein 
vesicles showed that the lipid had no significant effect 
on macrophages.
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^ 5• Effect of Reticuloendothelial System Sup­
pression of Low Density Lipoprotein (LDL) 
Metabolism In Vivo.
6.5.1.: Muramyl Dipeptide Conjugated to Acetylated 
Albumin (MDP-Ac-BSA).
The effect of MDP-Ac-BSA on the metabolism of LDL in vivo 
was determined in rabbits. The animals were injected 
with 125%-LDL and ^^^I-reductively methylated LDL 
( 1 3 1 i>.met-LDL) and the plasma clearance rates of the two 
tracers followed until they had reached terminan expon­
ential (Fig. R 2 1 ) . . At that point MDP-Ac-BSA was
administered (1.1 mg MDP/kg body weight) intravenously 
and within seven hours the plasma clearance rate slowed 
to 43.7% of control rate for native-LDL and 41.9% of 
control rate for Met-LDL (Table R2) . These slower rates 
of clearance of the tracers persisted for a further 24 
hours both returned to control values.
6.5.2.: Muramyl Tripeptide in Triolein Vesicles (MTP- 
Triolein).
The effect of MTP-triolein on the metabolism of LDL 
2 vivo was determined in rabbits. The animals were 
injected with 125i_ldl and 131%-Met-LDL and the plasma 
clearance rates plotted against time until the decay was 
monoexponential (Fig. R22). At this time, MTP-triolein 
(1 mg MTP/kg body weight) was administered intravenously 
and within 5 hours the plasma clearance rate for native-
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LDL had slowed to 36,1 ± 11.0% (n = 4) of the control 
rate and to 51.75 ± 7.7% (n = 4) for met-LDL (Table R2 ) . 
These slower rates of clearance of the tracers were 
significantly different from the control rates at the 0.1 
percent level and persisted for a further 40 hours before 
remitting.
6.6: Effects of Reticuloendothelial System
Suppressants on the Degradation of Lipo­
proteins by Cultured Macrophages.
6.6.1.: Effect of MDP-Ac-BSA on the Degradation of
Native and Met-LDL.
J774 mouse macrophages were treated with 0, 100, 250 and 
500 /ig/ml of MDP-Ac-BSA. These concentrations were 
measured in terms of the amount of albumin present and 
were equivalent to 0 , 80 , 200 and 400 jug/ml of MDP. After 
18 hours preincubation with the above concentrations of 
MDP-Ac-BSA the cells were challenged for their ability to 
degrade native and met-LDL (Fig. R23 and Fig. R24 
B«'Sppetivel-y ).; A'ft-ët 6 fadijCB of preinCubatiod'Wïth 250'ug 
lifS.- «oÿ-Ag-.BS'A the amoant of' nat#:e,%DÏ, jSëdueed to
79% of the control value and 500 pg MDP-Ac-BSA/ml to 60% 
of control value (Fig. R23). 100 jug M D P - A c - B S A / m l
reduced the amount of catabolism by as much as 250 ^ g / m l . 
The r eason for this was unclear but the effect was 
observed in other parameters measured during the experi 
" ment and was perhaps a real effect of dose dependence.
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The catabolism of met-LDL was reduced by 
42.2% and 46.7% by 250 and 500 pg MDP-Ac-BSA/ml respec­
tively (Fig. R24) in 6 hours. 500 pg Ac-BSA/ml of 
culture medium, however, produced a reduction in 
degradation of the markers of only 6% (Fig. R23) demon­
strating that the carrier was not significantly affecting 
cell catabolic function. Dose response curves were 
constructed for MDP-Ac-BSA (Fig. R25) and showed that, 
for both native and methylated LDL, there was an 
efficient suppression at 100 jug MDP-Ac-BSA/ml and there 
after increasing amounts produced a steady but slower 
decline in the ability of the macrophages to degrade the 
tracers. Cell protein was measured in each concentration 
group and expressed as mg of cellular protein/ml of 
culture medium (Fig. R26). Treatment with the suppressant 
produced a significant reduction in the amount of protein 
present, with the most marked drop occurring after 
incubation with 100 ug MDP-Ac-BSA/ml (64.5% of control 
value). Ac-BSA alone did not reduce the amount of 
cellular protein present (p > 0.5).
The decrease in cellular protein was likely 
to reflect a reduction in the number of cells present, 
perhaps by inhibition of cell replication and this was 
compensated for in calculation of the ability of macro­
phages to degrade the LDLs (ie degradation was expressed 
as the amount of 125% or ^^^I-tyrosine produced per ug of 
cellular protein).
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FIGURE R23: 125Degradation of I-LDL by Cultured Macrophages 
(J774) after Exposure to MDP-Ac-BSA.
The cells were exposed to MDP-Ac-BSA for 18 hours
then challenged with 150 ^g/ml (SL x 10^ cpm/ml ) 
125
of 1-LDL.
A : control
A : cells preincubated with 100 pg/ml MDP-Ac-BSA 
(80 pg MDP)
o ; cells preincubated with 250 pg/ml MDP-Ac-BSA 
(200 pg MDP)
• : cells preincubated with 500 pg/ml MDP-Ac-BSA 
(400 pg MDP)
rh€ macrophages were also treated with 500 pg/ml 
Ac-BSA (lAr) .
(each point was the mean of duplicate experiments)
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FIGURE R24; Degradation of ^^^I-Met-LDL by Cultured Macrophages 
(J774) after Exposure to MDP-Ac-BSA.
The cells were exposed to MDP-Ac-BSA for 18 hours 
then challenged with 150 pg/ml (1 x 10^ cpm/ml) of 
^^^I-Met-LDL.
A : Control
A : cells preincubated with 250 pg/ml MDP-Ac-BSA 
(200 pg MDP)
#: cells preincubated with 500 pg/ml MDP-Ac-BSA 
(400 pg MDP)
(each point was the mean of duplicate experiments)
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FIGURE R25: Dose Response Curve for Increasing Concentration 
of MDP-Ac-BSA in Cultured Macrophages (J774).
O; Effect of increasing dose of MDP-Ac-BSA on the
degradation of 125 I-LDL.
Effect of increasing dose of MDP-Ac-BSA on the
degradation of 131 I-Met-LDL.
The concentration of MDP-Ac-BSA was determined as 
BSA equivalents. 500 pg of MDP-Ac-BSA measured 
as BSA equivalents contains 400 pg MDP, Degradation 
was calculated 6 hours after experiment, began.
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FIGURE R26: Effect of Increasing Concentration of MDP-Ac-BSA
on Cellular Protein.
A: 500 fig/ml MDP-Ac-BSA {n = 8)
B; 250 jig/ml MDP-Ac-BSA (n = 8)
Ci 100 Jiig/ml MDP-Ac-BSA (n = 7)
D: control (0 pg/ml MDP-Ac-BSA) (n
E: 500 jjg/ml Ac-BSA (n = 3)
= 8)
unpaired t-test
control vs A p <0.01 
control vs B p <0.01 
control vs C p <0.01 
control vs E p >0.5
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6.6.2: Effect of MDP-Ac-BSA on the Degradation of
3-VLDL by Cultured Macrophages
J774 mouse macrophages treated with 500 ug of MDP-Ac-BSA 
per ml culture medium were shown to degrade g-VLDL at a 
much reduced rate compared to that of control cells and 
those treated with 500 ug Ac-BSA/ml (Fig. R 2 7 ). LDL 
degradation, measured at the same time, was also reduced 
and although much more 3-VLDL than LDL was degraded the 
reduction after treatment with MDP-Ac-BSA was similar 
(55% for 3-VLDL and 51% for LDL; Fig. R28).
6.7: Examination of Control Rabbit LDL and LDL
from Rabbits Treated with MDP-Ac-BSA or Ethyl 
Oleate by Ion Exchange Column Chromato­
graphy.
Control rabbit LDL (LDL) subjected to ion exchange column 
chromatography with an increasing sodium chloride 
concentration gave a single protein peak (Fig. R29) which 
eluted when the conductivity of the NaCl solution was
6.50 ± 0.45 mMHO (Fig. R32).
LDL from rabbits treated with MDP-Ac-BSA 
(MDP-LDL) produced two peaks under the conditions
described above (Fig. R30). The peak which eluted first 
(P 1 -MDP-LDL) was collected in sodium chloride solution 
with a conductivity of 6.85 ± 0.37 mMHO which was not 
significantly different from that of LDL (Fig. R32), 
however, the second peak eluted in sodium chloride
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FIGURE R27
3
TIM E
4
hours
Degradation of LDL and 3-VLDL by Cultured Macrophages in the Control 
State and After Treatment with MDP-Ac-BSA.
O 3-VLDL control 
□ LDL control
V  3-VLDL + 500 pg/ml Ac-BSA 
A  LDL + 500 pg/ml Ac-BSA 
• 3-VLDL + 500 pg/ml MDP-Ac-BSA 
■ LDL t 500 pg/ml MDP-Ac-BSA
(each point was the mean of duplicate experiments)
Zage
control
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FIGURE R28; Effect of MDP-Ac-BSA on the Degradation of 3VLDL 
and LDL by Cultured Macrophages (J774).
Percent of the amount of degradation of VLDL or 
LDL occurring in the control state after 7 hours 
incubation.
A; 3VLDL control
B: 3VLDL after treatment with Ac-BSA 
C: 3VLDL after treatment with MDP-Ac-BSA 
D; LDL control
E: LDL after treatment with Ac-BSA 
F: LDL after treatment with MDP-Ac-BSA
(each point is the mean of duplicate experiments)
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solution of conductivity 7.90 ± 0.35 mMHO which was 
significantly different from LDL (p<0.001; Fig. R32).
LDL from rabbits treated with ethyl oleate 
(PE-LDL) yielded one protein peak in NaCl solution of 
conductivity 7.17 ± 0.38 mMHO (Fig. R3 1) which was
significantly different from LDL at the 2% level 
(Fig. R32).
The difference between the MDP-LDL and PE-LDL 
may arise from various sources, for example rabbits 
treated with MDP-Ac-BSA are in the acute phase of RE 
suppression whereas rabbits receiving ethyl oleate are 
injected over a period of days and are in a new steady- 
state, chronic phase. As has already been shown (section
6.1.2.) uptake of MDP-Ac-BSA by the RE system does not 
follow the same pattern as uptake of lipid vesicles and 
this may also give rise to differences.
6.8: Examination of Control Rabbit LDL and LDL
from Rabbits Treated with Ethyl Oleate 
(PE-LDL) by Continuous Gradient Density 
Ultracentrifugation.
Control LDL and PE-LDL were labelled with l^l^ and 
respectively and centrifuged at 39 ,000 rpm for 18 or 24 
hours in a gradient of sodium bromide from 1.010 - 
1.060 kg/1 in 0.010 kg/1 steps. At the end of that 
period the gradient was continuous, as determined by 
refractometry, and was sampled in 0.5 ml aliquots which 
were then assayed for their content of radioactive
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FIGURE R32: Protein Peak Conductivities for Control LDL, 
and LDL from Rabbits Treated with MDP-Ac-BSA 
or Ethyl Oleate.
A; Control LDL;- 6.50 + 0.45 mMHO 
B : First eluted peak from MDP-Ac-BSA treated 
Rabbit LDL:- 6.85 + 0.37 mMHO.
C : Second eluted peak from MDP-Ac-BSA treated 
Rabbit LDL:- 7.90 + 0.35 mMHO.
D: Ethyl oleate treated Rabbit LDL:- 
7.17 + 0.38 mMhO.
unpaired t-test
control LDL (n = 6) vs B (n
control LDL (n = 6) vs C (n
control LDL (n = 6) vs D (n
4) p > 0.10 
4) p < 0.001 
7) p <0.02.
80 .
lipoprotein. I^^I-LOL yielded a single radioactive band 
which was most concentrated at a density of 1 . 0298 
± 0.0013 kg/1 (Fig. R33; Table R 3 ). 125i_pE_LDL was 
found to have two radioactive bands (Fig. R34), the first 
(P-I-PE-LDL) was concentrated in sodium bromide solution 
of density 1 .0274 ± 0.0010 kg/1, which was significantly 
less than control LDL (p < 0.02; Table R3 ) . P-|-PE-LDL 
was also significantly different form the second band 
which had a mean density of 1.0415 ± 0.0010 kg/1 at the 
0.1% level. P 2 -PE-LDL was significantly denser than 
control LDL (p < 0.001; Table R4).
Ethyl oleate treated rabbit LDL, then, 
appears to contain two species separable by density but 
not by ion exchange column chromatography. These bands 
equilibrate in solutions of density 1.0274 and 
1.0415 kg/1 because centrifugation for 24 hours instead 
of 18 hours does not alter the fractions in which they 
are found (results included in calculation of mean 
values).
6.9: Cholesterol to Protein Ratio in Control
Rabbit LDL and in LDL from Rabbits Treated 
with Ethyl Oleate (PE-LDL).
Protein content of the LDLs was determined and expressed 
in mg/dl, cholesterol concentration was also expressed in 
these terms and the ratio of cholesterol to protein 
content of each species of LDL calculated. Control LDL 
had a cholesterol/protein ratio of 0.70 ± 0.13 which was
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significantly lower than that for total PE-LDL at 1.10 
± 0.04 (p < 0.01; Table R4).
6.10: Plasma Clearance of Control LDL and LDL from
Ethyl O l e a t e  T reated R a b b i t s  (PE-LDL) in
Control Rabbits.
131l-LDL and 125i_pg_LDL were injected simultaneously in 
control rabbits and the decay of radioactivity from the 
plasma recorded (Fig. R35). PE - L D L  was removed faster 
than control LDL, the fractional clearance rate (FCR) for 
PE- L D L  being 3.41 ± 0.31 pools per day and the FCR for 
control LDL being 1.83 ± 0.26 pools per day (p << 0.001; 
Table R5).
After 30 hours the animals were anaesthe­
tised, exsanguinated and uptake of radioactive tracer 
into a range of tissues determined (Fig. R36). This 
tissue uptake of radioactivity was expressed as the 
difference between the relative uptake of control LDL and 
PE-LDL. The liver, spleen and adrenals showed the largest 
difference when this parameter was calculated per gram of 
tissue, catabolising larger amounts of PE-LDL. Difference 
in relative uptake for whole organs revealed that the 
liver was the most important organ in the degradation of 
PE-LDL (Fig. R37), being more than 350 fold as active as 
the spleen. It was noted that the tissues showing larger 
uptakes of PE-LDL over control LDL were rich in macro­
phages of the RE system (section 4, 158).
100
50-
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TIM E days
FIGURE R35: Plasma Clearance Rates of Control Rabbit LDL and LDL from
Rabbits Treated with Ethyl Oleate in Control Rabbits;
500 ug (1 X lO^cpm) of ^^^I-LDL and ethyl oleate treated
rabbit LDL (^^^I-PE-LDL) were injected into control rabbits; 
The plasma clearance rates of each tracer was followed for 
30 hours and expressed as percent injected dose ;
■ : control LDL 
A  : PE-LDL
TABLE R5;
FCR 
CONTROL LDL 
(pools/day)
FCR
PE-LDL
(pools/day)
1.57 3.17
1.65 3.40
2.00 3.43
2.11 3.43
3.96
3.42
2.86
3.16
3.47
3.76
1.83 + 0.26 3.41 + 0.31
Unpaired t-test vs control p «0.001
Table shows fractional catabolic 
rate (FCR) in pools per day for 
clearance of control LDL and ethyl 
oleate treated rabbit LDL (PE-LDL).
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FIGURE R36: Difference in Relative Tissue Uptakes of ^^^I-LDL
and 131 I-PE-LDL in NZW Rabbits.
30 hours after the injection of the tracers the 
animals were exanguinated and the relative tissue 
uptakes were calculated.
Relative Tissue Uptake = ^Pm/gram^tissue
The RTU for control LDL was subtracted from the 
RTU for PE LDL (n = 4) to demonstrate those tissues 
which had the highest affinity for PE LDL. The 
aorta comprised two sections which were;
1) the arch and upper thoracic and
2) the lower thoracic and upper abdominal.
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FIGURE R37; 125Difference in Relative Uptakes of I-LDL 
131
and I-PE LDL in the organs of NZW 
Rabbits.
Total organ uptake was calculated from
the relative organ uptake of each tracer
times the weight, in grams, of the organ.
The difference between ^^^I-PE LDL and 
125 I-LDL was then determined.
82.
6.11: Competition for the Acetyl-LDL Receptor on
Macrophages by Control Rabbit LDL, Human LDL 
and LDL from Ethyl Oleate Treated Rabbits 
(PE-LDL).
125i_;^cetyl-LDL degradation was measured in J774 mouse 
macrophages and compared to the amount of degradation 
which occurred in the presence of measured amounts of 
competitor. Increasing amounts of human and control 
rabbit LDL reduced Ac-LDL catabolism by only 20% and 30% 
respectively when 1,000 ;ug LDL protein/ml was present 
(Fig. R38 and R39). PE-LDL, however, was able to reduce 
the amount of Ac-LDL degradation to less than 20% of the
control value at a concentration of 1000 ug LDL protein/ml 
(Fig. R38 and R39). EDTA at a concentration 10 fold 
greater than working concentrations had no effect on the 
degradation of Ac-LDL. ____________
The results obtained in these experiments 
were plotted to demonstrate increasing inhibition of 
Ac-LDL degradation with increasing concentrations of the 
LDLs (Fig. R40).
Fibroblasts were challenged with ^^^I-LDL and 
131I-PE-LDL and the degradation of the two markers 
determined as described. These cells did not degrade 
PE-LDL faster than control LDL (Fig. R41), supporting 
further the evidence that macrophages of the RE system 
are responsible for the catabolism of PE-LDL.
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FIGURE R40; 125Competition with I-Ac-LDL by Control 
Rabbit LDL, Human LDL and PE-LDL for the 
Acetyl LDL Receptor on Cultured Macrophages
• ; PE-LDL
▲ : Human LDL
■ : Control Rabbit LDL
4 0
2 0
10
Od
LU
2 4 6 8
T IM E  hou rs
FIGURE R41: Degradation of Control Rabbit LDL and 
Ethyl Oleate Treated Rabbit LDL (PE-LDL) 
by Cultured Fibroblasts.
o : PE-LDL 
• ; Control LDL
(Each point was the mean of duplicate 
experiments).
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6.12: Clearance of Control LDL, after Reisolation
from Control Rabbits and from Rabbits Treated 
with Ethyl Oleate, from the Plasma of Control 
Rabbits.
LDL from the plasma of control rabbits was divided into 
two aliquots and labelled with 125i and 1^1j, The 
125%-LDL was injected into control animals and the 131'- 
I-LDL into ethyl oleate treated animals. After 48 hours 
the radiolabelled LDLs were reisolated. Agarose gel 
electrophoresis showed that the LDL reisolated from ethyl 
oleate treated rabbits had a higher electrophoretic 
mobility (towards the anode) than the LDL from the 
control rabbits (Fig. R42). Both tracers were injected 
simultaneously into control animals and plasma clearance 
rates measured. Plasma clearance of the LDL incubated 
in vivo in ethyl oleate treated rabbits was greater than 
that incubated in control animals (Fig. R43). Screening 
in treated rabbits appears to confer the properties of 
PE-LDL onto injected control LDL.
6,13: Clearance of PE-LDL and Control LDL, after
Reisolation from Control Rabbits, from the 
Plasma of Control Animals.
125i _p e _ l d l  was injected into the plasma of control 
rabbits and the radioactivity in the LDL density range 
reisolated 24 hours later. 131i-l d l was treated in the 
same way in separate animals. Both LDLs were then 
injected, together, into control rabbits. Agarose gel
500t
400"
300
Euir>
200 -
&100
V
3 4 5 6 7 8
DISTANCE FROM O RIG IN  
(O'Scm units)
9 10
FIGURE R42: Agarose Gel Electrophoresis of Control LDL
Screened in Control and Ethyl Oleate 
Treated Rabbits.
■ : Control LDL screened in vivo in an 
Ethyl Oleate Treated Rabbit.
Control LDL screened in vivo in a 
Control Rabbit.
Run Time - 30 minutes.
© indicates direction of anode
50
•  control LDL screened in ethyl oleate rabbit 
■ control LDL screened in control rabbit
0*2 0*40 0-6 08 1210
TIME days
FIGURE R43; Plasma Clearance of Control LDL Biologically 
Screened in Control and Ethyl Oleate Treated 
Rabbits.
125 I-LDL was injected into control rabbits
131and reisolated 48 hours later, ^^^I-LDL was 
injected into ethyl oleate treated rabbits 
and reisolated 48 hours later. The two 
tracers were then injected simultaneously 
into control animals and the plasma clearance 
rates followed for 30 hours.
(n = 5 in both cases)
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electrophoresis failed to show any difference in electro­
phoretic mobility of the two LDLs (Fig. R44) and, 
further, there was no difference between these LDLs and 
the electrophoretic mobility of control LDL reisolated 
from control rabbits (section 6.12; Fig. R42).
Plasma clearance from control rabbits 
occurred at the same rate for both LDLs (Fig. R45) and it 
was noted, at the same rate as the LDL incubated in 
control rabbits (Fig. R43).
6.14: Effects of Cholesterol Feeding and Ethyl
Oleate on the Plasma Clearance of Native and 
Met-LDL in Rabbits.
Plasma clearance rates were determined for native and 
met-LDL in two groups of rabbits. Group 1 received a 
diet supplemented with 1% cholesterol for 40 days and 
were injected with ethyl oleate emulsion twice per week 
for the duration of the experiment. The second group 
were fed the same diet for the same time but received no 
ethyl oleate.
In group 2, there appeared to be a slight 
difference between the clearance rates for the tracers, 
native-LDL being removed faster (Fig. R46). However, on 
calculation of fractional clearance rates this difference 
was shown to be not significant (p>0.5; Table R6 ) . In 
group 1, receiving ethyl oleate, there was no difference 
in the rate of removal of the tracers (Fig. R 4 7 ) as 
confirmed by calculation of their FCRs (Table R7). There
0T
I
Euin
o
2
1 2 3 4 5 6 7 8 9  10
DISTANCE FROM O R IG IN  
(O'Scm units)
FIGURE R44: Agarose Gel Electrophoresis of Control LDL
and PE-LDL Biologically Screened in Control 
Rabbits.
A : Control LDL screened in vivo in a control 
animal.
■ ; PE-LDL screened in vivo in a control 
animal.
Run Time = 30 minutes, 
t ©  indicates direction of anode)
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FIGURE R45: Plasma Clearance of Control and Ethyl Oleate Treated Rabbit LDL
after Biological Screening in Control Rabbits.'
131
I-LDL was injected into control NZW rabbits and reisolated 
after 24 hours;
125
I-PE-LDL was injected into control NZW rabbits and reisolated 
after 24 hours. The tracers were then injected simultaneously into 
control animals and their plasma clearance rates followed for 
30 hours.
o :
125
131
I-PE-LDL reisolated from control animals 
I-LDL reisolated from control animals.
(n = 3)
100
70
50 -
IJ so ­
il
8, 20- 
O
0 0-80-4 2012 16
TIM E  days
FIGURE R46; Plasma Clearance of ^^^I-LDL and ^^^I-Met 
LDL in NZW Rabbits Fed a Cholesterol Rich 
Diet.
• ; Met-LDL (n = 5) 
o ; Native-LDL (n = 5)
see Table R 6 ,
RABBIT NO.
FCR
NAT-LDL
FCR
MET-LDL
6 0.87 -
7 0.77 0.58
8 0.50 0.51
9 0.84 0.64
10 0.62 0.58
MEAN 
+ 1 S;D.
0;72 + 0;15 0.58 + 0v05
TABLE R6:
unpaired t-test Met LDL vs Nat LDL p > 0.05
Fractional catabolic rate (FCR) for native 
LDL (NAT-LDL) and reductively methylated-LDL 
(MET-LDL) in cholesterol fed animals;
100
50
I
^  30I 
§. 20-
0 04 0-8 1-2 201*6
TIME days
FIGURE R47: Plasma Clearance of ^^^1-native LDL and ^^^1- 
Met LDL in NZW Rabbits Fed Cholesterol Rich 
Diet and Treated with Ethyl Oleate.
• : Met-LDL (n = 5) 
o : Native-LDL (n = 5)
see Table R7.‘
RABBIT NO;
FCR FCR
NAT-LDL MET-LDL
1 0.81 0.79
2 0.63 0.61
3 1:04 1.22
4 0.69 0;58
5 0;76 0.92
MEAN
0.78 + 0.15 0.79 + 0;27
+ 1 S.D;
TABLE R7: unpaired t-test nat-LDL vs met-LDL p »  0.5
Fractional catabolic rate (FCR) for native 
LDL (NAT-LDL) and reductively methylated- 
LDL (MET-LDL) in rabbits fed a cholesterol 
rich diet and receiving twice-weekly 
injections of ethyl oleate emulsion;
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was no significant difference between the rate of removal 
of tracers from group 1 and group 2 (p>0.1).
6.15: Effect of Cholesterol Feeding and Ethyl
Oleate on the Development of Atherosclerosis 
in Rabbits.
The percentage of atherosclerotic aortae {(weight of 
affected areas/weight of aorta) x 100) was compared 
between two groups of 5 rabbits. Group 1 received a diet 
supplemented with 1% cholesterol for 40 days and were 
injected with ethyl oleate twice per week for that time. 
Group 2 received the same diet as group 1 but were not 
treated with ethyl oleate. At the end of the 40 day 
period the rabbits were anaesthetised, exsanguinated and 
their aortae removed. The percentage affected areas were 
calculated for both groups (Table R 8 ). Group 1 had a 
significantly higher percentage of affected surface area 
than group 2 (p < 0.001; two of the worst affected aortae 
from each group are schematically represented in 
Figure R48), despite the fact that there was no differ­
ence in total cholesterol levels between the groups 
(Fig. R12). Agarose gel electrophoresis of LDL from two 
animals of each group revealed that LDL from ethyl oleate 
treated group 1 had a higher anodic mobility than that 
from group 2 (Fig. R49).
TABLE R8:
TREATMENT
ETHYL OLEATE 
PLUS 
CHOLESTEROL 
FEEDING
CHOLESTEROL
FEEDING
ONLY
1 24.03 3.47
2 44.71 5.43
3 47.97 7.79
4 77.92 14.61
5 89.03 27.77
MEAN .+ 1 S.D.
a
56.73 + 26.38
a
11,81 + 9.86
Affected Areas of the Aortae of NZW Rabbits
Fed a Cholesterol Rich Diet and Treated with 
Ethyl Oleate;
a: unpaired t-test cholesterol diet vs
cholesterol diet + ethyl oleate p< 0;001
Percent of the surface area of the aortae 
which were affected by fatty infiltration and 
raised plaques after feeding with a cholesterol 
rich diet or treatment with ethyl oleate and 
a cholesterol rich diet;
See Fig. R48.
B\
FIGURE R48: Aortae from Group 1 and Group 2 NZW rabbits.
Representations of the aortae of 2 animals 
from group 1 (cholesterol feeding and ethyl 
oleate). The shaded areas represent affected 
intima (A:89%, B;78% affected). C and D are 
aortae from rabbits which received only the 
cholesterol rich diet and were 28% and 15% 
affected, respectively.
origin
lane
FIGURE R49: Agarose Gel Electrophoresis
Schematic Representation of;
Lane 1. LDL from Cholesterol fed 
Rabbit.
Lane 2. LDL from Cholesterol fed 
Rabbit.
Lane 3.) LDL from Cholesterol fed
) Rabbits treated with ethyl 
Lane 4.) oleate.
Run Time 50 minutes.
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7; DISCUSSION
7.1: General Discussion
Cells of the reticuloendothelial system (RE-system) 
include tissue macrophages (or histiocytes), alveolar and 
peritoneal macrophages and the endothelial macrophages of 
blood sinusoids. These cells are able to phagocytose 
particulate matter of macromolecular size, such as 
colloidal suspensions of dye stuffs (158). They are also 
thought to play an important role in atherosclerosis. 
There is evidence to show that they are the precursors of 
foam cells found in atherosclerotic plaques (7,8,11).
When endothelial cells lining the aorta are 
damaged by mechanical (13,14), chemical (15) or 
immunological (16) insult, insudation of blood components 
into the intima occurs (5). Monocytes migrate into the 
artery wall from the lumen, becoming histiocytes (7,11). 
These cells may be present, originally, to phagocytose 
and degrade blood components (such as lipoproteins) and 
to remove damaged cells and matrix components in an 
attempt to prevent necrosis of the lesion. However, it 
is postulated that macrophages along with platelets, 
which aggregate at the site of endothelial damage, 
release highly active growth factors (17,19). These 
growth factors are chemotactic to smooth muscle cells and 
promote their migration from the media and proliferation 
in the intima. In addition there is evidence that growth
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factors increase the number of LDL receptors present on 
the surface of smooth muscle cells (17), promoting uptake 
of that lipoprotein by these cells.
The concentration of LDL in the intima is 
dependent on the plasma level of the lipoprotein (27). 
In cases where this is high macrophages catabolise large 
amounts of LDL. These cells catabolise little or no LDL 
by the LDL receptor pathway (139) but alternative routes 
are available for the assimilation of the lipoprotein. 
They will be discussed in detail below. The macrophages 
become engorged with lipid, especially cholesteryl ester, 
to the extent that they may form foam cells (7,11).
Macrophages, endothelial cells and vascular 
smooth muscle cells appear to release oxidising free 
radicals (172,173). These highly reactive chemical 
agents may cause further damage to cells and matrix 
components in the aorta. Previously published results 
demonstrate that free radicals can react with LDL 
(171,172) causing changes which increase uptake by 
macrophages.
Thus monocyte derived histiocytes which are 
present at the sites of damage to the aorta to aid in the 
repair process become contributing factors in athero­
sclerosis.
Receptor dependent catabolism of LDL is a 
reasonably well understood process (61,53,87,90,91). LDL 
and certain other lipoproteins which contain apolipo- 
protein B (apoB) or apoE are ligands for a specific
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receptor associated with the cell membrane. Many types 
of cell have been shown to express this receptor (61,62). 
After binding of the ligand lipoprotein to the receptor 
it is internalised in a receptosome and degraded by 
hydrolysis in lysosomes (66). Cholesteryl ester is 
hydrolysed and free cholesterol released into the 
cytoplasm. This cholesterol has various effects on 
cellular processes. There is a stimulation of 
cholesterol ester formation, a decrease in cellular 
cholesterol synthesis and a down regulation of receptor 
uptake of LDL (90,91). In normal individuals, one third 
to one half of the plasma LDL pool is catabolised via the 
LDL receptor, depending on the LDL pool size of the 
subject (92,93,94).
Individuals with the disease familial 
hypercholesterolaemia have a genetically determined lack 
of functional LDL receptors (90). In heterozygous 
sufferers receptor dependent LDL degradation is reduced 
by about 50% (94). The fully affected homozygous form is 
manifested by a complete lack of functional LDL receptors 
(92). This results in grossly elevated plasma LDL 
levels. Despite the lack of LDL-receptors total 
catabolism of the lipoprotein is increased in these 
individuals (92). Clearly another mechanism, independent 
of the receptor system, is operational. It also seems to 
be responsible for degradation of at least one half of 
the LDL pool in normal subjects. This catabolic 
mechanism has been termed the receptor independent or
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scavenger pathway but is still poorly understood (155). 
The reticuloendothelial system has been implicated as 
part of the scavenger mechanism (102,155). Macrophages 
are an important part of the RE system (158). They have 
a greater capacity for non-specific uptake and catabolism 
of LDL. Pittman has, however, demonstrated that, 
although this process contributes to the receptor 
independent pathway, the contribution is limited even at 
high plasma levels of LDL (157).
Macrophages express few LDL receptors in 
culture (139) and thus do not degrade LDL by the LDL 
receptor pathway. In familial hypercholesterolaemia the 
receptor does not function but macrophages from these 
subjects still degrade large amounts of LDL (102). In 
patients with myeloproliferative disease the RE-system is 
hyperactive (174). Studies have shown (99,100) that such 
individuals catabolise LDL and chemically modified LDL 
(which does not interact with the LDL receptor) at a 
significantly increased rate. Receptor dependent 
catabolism is unaffected.
It is evident that some mechanism for the 
degradation of LDL by macrophages is functioning 
independently of the LDL receptor.
Cells of the RE-system have been shown to 
degrade LDL chemically modified in such a way as to 
increase its net negative charge. These modifications 
include citraconylation (103), maleylation (139), 
malondialdehyde treatment (140) and acétylation
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(103,139). The process was found to be mediated by a 
receptor on macrophages which was specific for negatively 
charged proteins (139). It was denoted the acetyl-LDL 
receptor (Ac-LDL receptor). In contrast to the LDL 
receptor, the Ac-LDL receptor is not down regulated by 
influx of cholesterol into the cell (139). Consequently 
large amounts of LDL can be catabolised by this route, 
leading to massive deposition of sterol in the cell.
There is some evidence for the formation of 
chemically modified LDL, which serves as a ligand for the 
Ac-LDL receptor, in vivo (145). Substances such as 
malondialdehyde, released during the oxidation of 
arachidonic acid by aggregating platelets, have been 
shown to modify LDL so that the product interacts with 
the macrophage receptor. Although the concentration of 
this substance in the plasma is low it may reach 
appreciable levels in the microenvironment of platelet 
thrombi. This may be of some consequence in the 
formation of foam cells since one of the sequelae 
associated with atherosclerosis is platelet aggregation.
Oxidation of LDL by free radicals has been 
shown to occur in vitro. The primary action appears to 
be on the lipids of the lipoprotein but may produce a 
secondary effect on the apolipoprotein moiety (171,172). 
Such secondary effects include breakage of peptide bonds, 
loss of amino acids and crosslinking (171). There is 
evidence that oxidation converts LDL to a form recognised 
by the Ac-LDL receptor (172). Macrophages and endo­
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thelial cells release superoxide ions (172,173) which are 
active alone or can generate highly reactive free 
radicals. It is postulated that this oxidation may have 
some role in LDL degradation by macrophages in athero­
sclerotic plaques.
Hendriksen (142,147) has reported that 
incubation with endothelial cells and aortic smooth 
muscle cells in vitro converts LDL into a form recognised 
by the macrophage receptor. This EC-modified LDL was 
found to have altered physical and chemical 
characteristics. The density of the particle increased 
as did its electrophoretic mobility (overall negative 
charge). The cholesterol/protein ratio of EC-modified 
LDL was lower than that for control LDL. This lower 
ratio may explain the increase in density of the altered 
lipoprotein; increased protein or, more likely, decreased 
cholesterol content is consistent with higher density in 
lipoproteins. These changes did not occur if LDL was 
incubated with endothelial cell conditioned medium. It 
was shown that the increase in average density was not 
due to preferential degradation of a lower density 
fraction of LDL by endothelial cells. The cells 
catabolised less than 10% of the total amount of lipo­
protein present (147).
Several mechanisms were considered to explain 
the changes observed in LDL:
a) chemical modification (103,139,140) would 
produce an increase in net negative charge of the
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lipoprotein (125,126,127). However, this has been shown 
not to alter the density of the particle (93). Therefore 
it seems unlikely that chemical modification, alone, was 
responsible for changes observed.
b) passive or enzymatic alteration of LDL at 
the cell surface cannot be ruled out (147) but there is 
strong evidence that LDL is internalised by the cells. 
Conversion does not occur in the presence of inhibitors 
of endocytosis or at 4®C (147,178).
c) retroendocytosis is a process in which LDL 
that has been internalised via the LDL receptors is 
excreted from the cell without being degraded in 
lysosomes ( 1 42 , 1 47 ). It has been suggested that retro- 
endocytosis may be a widely occuring cellular process but 
the mechanism is not well understood. Removal of 
material from, or addition to, LDL may occur within the 
cells (147) possibly inducing conformational changes in 
the particle or complexing with sulphated polysaccarides 
or proteoglycans.
d) most convincing, however, is the finding 
by Morel (172) that inclusion of antioxidants or free 
radical scavengers in the medium prevent the physical and 
chemical changes observed on incubation of LDL with 
endothelial cells. These cells are capable of producing 
superoxide ions (173) which may react with the internal­
ised lipoprotein converting it to the form recognised by 
the Ac-LDL receptor.
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It has been shown that retroendocytosis in 
vitro occurs in many cell types and is quantitatively 
significant (175). Despite this the evidence for such a 
mechanism occurring in vivo is scarce. No EC-modified 
LDL has been found in the plasma but this observation is 
not unexpected. If altered LDL were generated by, for 
example, endothelial cells of the blood vessels, it would 
be rapidly catabolised by macrophages of the RE-system 
through the Ac-LDL receptor (142,147). This rapid 
removal from the plasma would mean that concentrations 
were normally very low.
There is some evidence for similarly altered 
LDL in the interstitial fluid of rabbits (176). These 
particles have increased density and electrophoretic 
mobility. However, there are some differences between 
EC-modified LDL and LDL of interstitial fluid. The 
latter is larger and triglyceride enriched. These are 
properties usually associated with less dense lipo­
proteins (81). It is not known if interstitial fluid LDL 
is degraded rapidly by macrophages.
If LDL altered by the mechanisms described 
were present in the plasma its concentration would be 
very low. In hypercholesterolaemics, where the LDL 
receptor is defective, the Ac-LDL receptor still 
functions (139). In these individuals large amounts of 
the lipoprotein are degraded by the RE-system. The most 
important cells in this catabolism would be the 
endothelial macrophages of the liver and spleen (158).
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These cells have been shown to catabolise over 95% of 
markers of macrophage function in vivo (158). It is 
possible that larger amounts of altered LDL are produced 
in familial hypercholesterolaemics but, again, it would 
be catabolised rapidly by the still functioning RE-system 
macrophage receptors.
7.2; Suppression of the Reticuloendothelial
System
7.2.1: Agents Used to Achieve Suppression
According to the above argument, suppression of the 
RE-system might be expected to reduce catabolism of any 
lipoprotein normally degraded by that route and cause an 
increase in plasma concentration of that lipoprotein.
Two agents were found to be particularly 
effective as suppressants of RE function:
1) Ethyl Oleate.
The monoesters of long chain fatty acids are 
well documented as inhibitors of the RE-system (131). 
Emulsions of lipid, including ethyl oleate, are cleared 
rapidly from the plasma by the RE-system (158). The 
liver and spleen are responsible for the clearance of 
most of the emulsion due to their content of macrophages
(158). This properly was exploited to deliver the 
inhibitory ethyl oleate, as an emulsion, specifically to 
these cells.
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2) Muramyl Peptides.
Bacterial cell walls contain peptide 
conjugates of N-acetyl muramic acid. These peptido- 
glycans are responsible for the endotoxic activity of the 
organisms (161). The minimum configuration which can 
mimic this effect is muramyl dipeptide (MDP). The 
adjuvant properties of MDP have been known for some time 
(16 0,161,162). More recently, however, the immuno­
suppressive properties of peptidoglycans have been 
recognised (165) and confirmation that MDP can also 
inhibit the RE-system reported (166,167).
These endotoxins have powerful effects on 
plasma lipid levels (163,164). Plasma triglyceride was 
shown to increase dramatically and resolve to base-line 
values within 24 hours of a single injection. 
Cholesterol levels did not increase as rapidly but 
remained elevated for longer periods (163,164). The 
mechanism of action of the endotoxins on lipid levels is 
little understood.
Two methods were successfully used to target 
MDP to the RE-system. Firstly, MDP can be attached to a 
phospholipid moiety through a third amino acid; this was 
denoted muramyl tripeptide phospholipid (MTP). Through 
the hydrophobic properties of the phospholipid the 
endotoxin was incorporated into an emulsion formed from 
glyceryl trioleate (triolein). Triolein emulsion was 
removed rapidly from the plasma of experimental animals 
(95% in 15 minutes) mainly by the liver and spleen.
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Secondly, the Ac-LDL receptor can recognise 
other acetylated proteins such as bovine serum albumin 
(Ac-BSA). Ac-BSA was also cleared from the plasma by the 
liver and spleen. The spleen, however, was less active 
in catabolism of acetylated protein than it was with 
triolein emulsion. This difference may be accounted for 
by liver endothelial cells. These are not endothelial 
macrophages (Kupffer cells) but have high affinity 
binding sites for acetylated proteins (159). It was 
shown (159) that these cells, although contributing less 
than 4% of total liver protein mass, contained 
approximately 50% of the Ac-LDL catabolised by the liver 
as a whole. There is, however, some evidence that these 
cells represented a subpopulation of actual endothelial 
cells present in the liver, rendering this estimate high
(159).
Total liver uptake of radioactive tracer was 
40% of the injected dose after 30 minutes. It is 
important to note that this is not a cumulative estimate 
and does not include catabolites of the tracer ( ie 
iodotyrosine) which were excreted back into the plasma.
7.2.2: Effects of RE-System Suppression In-Vivo
The effect of ethyl oleate and MTP-triolein on the 
activity of the RE-system was measured in vivo using the 
rate of clearance of colloidal carbon from the plasma of 
experimental animals before and after treatment. Kupffer 
cells take up approximately 90% of injected carbon
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particles and the splenic macrophages account for most of 
the remainder (131). Clearance of colloidal carbon is an 
established method for the determination of the level of 
RE activity (131). Phagocytic index (K) is calculated 
from the gradient of the graph produced by plotting the 
logarithm of plasma carbon concentration (determined by 
measurement of the optical density of the plasma at 
700 nm) against time.
Treatment with ethyl oleate or MTP-triolein 
reduced K to approximately 50% or 20% of control values, 
respectively (Fig.RiS). This demonstrates a significant 
reduction in activity of the RE-system. Redetermination 
of phagocytic index two weeks after treatment with 
MTP-triolein showed that, after that time interval, 
previously phagocytosed carbon particles had no 
suppressive effect on macrophages.
In previous studies (163,164) investigators 
found that administration of bacterial endotoxins 
produced a rise in plasma cholesterol and triglyceride 
levels. In this study similar effects were observed in 
the plasma concentrations of both lipids after treatment 
with ethyl oleate, MTP-triolein and MDP-Ac-BSA (Fig.R6- 
R9) .
The effects observed on treatment with 
MDP-Ac-BSA demonstrated that the lipid targeting systems 
used were not responsible for the rise in plasma lipids. 
This was supported by analysis of total plasma fatty 
acids. On administration of ethyl oleate no increase in
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plasma oleic acid (c 18 : 1 ) levels were noted despite the 
injection of a total of 6 grams of ethyl oleate over four 
days. Repeated injections of ethyl oleate produced a new 
steady level of plasma cholesterol. Analysis of lipo­
protein concentrations showed this to be almost entirely 
accounted for by an increase in the LDL level.
Seifter (163,164) found that the response of 
plasma cholesterol on administration of bacterial 
endotoxin did not follow the same pattern as that for 
triglyceride. It was suggested that the increase in 
cholesterol was due to either an increased mobilisation 
or a decreased utilisation of that lipid. In light of 
the results discussed here the latter of these 
possibilities seems more likely. The increase in plasma 
cholesterol was due to a decrease in catabolism of 
cholesterol rich lipoproteins (ie LDL) by the RE-system.
LDL which has been reductively methylated 
(met-LDL) does not interact with LDL-receptors 
(125,126,127) and so is a marker of alternative 
(scavenger) degradative mechanisms. Lipoproteins decay 
from the plasma in a biexponential manner. The terminal 
phase, known as the monoexponential phase, was used to 
examine the effects of RE-system suppressants on the 
catabolism of met-LDL and native LDL. The rate of 
monoexponential decay was reduced by approximately 50% on 
administration of MDP-Ac-BSA or MTP-triolein. It has 
been demonstrated that ethyl oleate has a similar effect
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(102), and that triolein emulsion alone elicited no 
suppressive effects on the plasma clearance of LDL.
The reduction in catabolism of both tracers 
suggests that treatment with suppressants mainly affects 
the scavenger pathway. Examination of a number of 
biochemical and haematological parameters after 
administration of RE-system suppressants revealed no 
significant changes in hepatic, thyroid or renal 
function. It did, however, show a small reduction in the 
number of circulatory white blood corpuscles but haemo­
globin and red cell morphology were unaffected.
Cholesterol feeding appeared to mask the 
effect of RE suppressants on plasma lipid levels. There 
was no difference between cholesterol levels in 
cholesterol fed animals and those also receiving ethyl 
oleate emulsion. This may result from the massive rise 
in plasma cholesterol which occurs on feeding of the 
sterol (reaching 50-60 mmolar in 40 days: Fig.Rl2,
ref.21). Triglyceride levels in the plasma of the two 
groups were not significantly different.
Starvation of control rabbits produced a 
slight rise in plasma cholesterol levels which was 
possibly due to a decreased utilisation of LDL by the 
liver for the production of bile. Simultaneous ethyl 
oleate treatment produced a rapid rise in cholesterol 
level which appeared to reach a new steady state by the 
fourth day. Starvation produced a mixed but small 
response in plasma triglyceride and treatment of these
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animals with ethyl oleate produced a rapid rise in 
triglyceride which resolved to control levels by the 
fourth day despite continued treatment. The reason for 
the transient response of triglyceride is unclear but may 
not be a product of RE-system suppression.
7.2.3: Effects of Re-System Suppression In Vitro
Formaldehyde denatured albumin has been known for some 
time to be an in vitro marker of macrophage function 
(168). It is rapidly degraded by cultured macrophages.
MDP or MTP dissolved in culture medium 
reduced the degradation of denatured albumin to less than 
13% and 4% of control values, respectively. This 
demonstrates the potency of these substances in affecting 
the catabolic processes of macrophages. Macrophages 
treated with MTP- tr iole in degraded less than 4% as much 
denatured albumin as control cells. This shows that the 
effects seen in vivo on the administration of MTP- 
triolein were a manifestation of the suppression of 
macrophages. Triolein vesicles alone had no significant 
effect on the degradation of denatured albumin but there 
was a short lag phase in macrophage function immediately 
after treatment. The reason for this is not understood.
Macrophages were also treated with ethyl 
oleate but cell death occurred even at low concentrations 
(15 pg lipid/ml culture medium). This observation was 
inconsistent with earlier work done in vivo (169) which 
suggested that treatment of animals with ethyl oleate
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resulted in suppression of macrophages without cell 
death.
Catabolism of lipoproteins by macrophages in 
culture was also reduced by preincubation of the cells 
with RE-system suppressants. MDP-Ac-BSA reduced LDL and 
met-LDL degradation to 61% and 53% of control rate 
respectively. It has been shown that J-774 mouse 
macrophages express very low numbers of LDL receptors 
(140,143), thus only small amounts of LDL are degraded 
via this route. This, along with the quantitative 
effects on the degradation of native and met-LDL, 
suggests that the LDL-receptor independent or scavenger 
pathway was affected by MDP-Ac-BSA.
Cell protein was shown to decrease as the 
concentration of MDP-Ac-BSA in the incubation medium 
increased. This probably indicates a reduction in cell 
numbers in each culture at the end of the incubation 
period. It is likely that this is due to an inhibition 
of cell replication. Cell division would proceed at 
normal rates in control cultures but be suppressed in 
treated cultures. This would reduce the amount of cell 
protein present in treated flasks when compared to 
controls. Cell death could be ruled out because the 
cells remained attached to the wall of the flask and 
there was no increase in the number of cells floating 
free in the medium (a sign of cell mortality) in cultures 
treated with MDP-Ac-BSA. Degradation of markers was 
calculated per microgram of cell protein so this factor
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was not responsible for the effects observed. Ac-BSA, at 
concentrations used to deliver MDP, had no significant 
effect on either LDL catabolism or cellular protein when 
compared to control values.
e-VLDL degradation was also greatly reduced 
by suppression of cultured macrophages with MDP-Ac-BSA. 
This lipoprotein is bound by a specific receptor on 
macrophages (73) which does not bind control LDL, Ac-LDL 
or control VLDL (73,74). MDP-Ac-BSA reduced catabolism 
of 3“VLDL by up to 55% compared with 57% for LDL measured 
concomitantly. B-VLDL are present at low concentrations 
in the plasma of normal animals but accumulate when the 
diet is rich in cholesterol (74). 'The suppression of 
B-VLDL degradation by macrophages indicates a general 
inhibition of catabolic activity. The significance of 
this effect in normal rabbit does not appear to be great, 
indeed, as has been stated, B-VLDL concentrations are 
very low in normal animals. In cholesterol fed animals, 
where the plasma concentration of B-VLDL is much higher, 
this reduced degradation might be expected to be more 
pertinent. However, treatment of cholesterol fed animals 
with ethyl oleate had no significant effect on the 
already grossly elevated plasma cholesterol levels. There 
is some evidence that B-VLDL receptors are to some extent 
down regulated by the influx of cholesterol into the cell 
(73) but whether this is sufficient to explain the 
similarity in cholesterol levels between RE suppressed 
and normal cholesterol fed animals is unknown. The
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effects of MDP-Ac-BSA on lipoprotein degradation by 
macrophages in culture are summarised in Figure R28.
It appears that macrophages in vitro were 
affected by RE-system suppressants. Their ability to 
degrade denatured albumin (a marker of the activity of 
cultured macrophages), LDL, met-LDL and B-vLDL was 
inhibited. These findings support the in vivo results 
discussed in section 7.2.2.
7.3: The Effects of Reticuloendothelial
Suppression on Low Density Lipoproteins
As has been discussed, LDL incubated with endothelial 
cells undergoes an increase in density, an increase in 
electrophoretic mobility and a decrease in cholesterol to 
protein ratio (142,147,148). Various mechanisms were 
proposed to explain this. The most likely of these 
appeared to be retroendocytosis following oxidation 
within the cell (171,172,173).
Treatment of rabbits with RE suppressants 
produces an increase in plasma LDL cholesterol levels. 
This LDL, which is normally degraded by the RE-system, 
may be the equivalent in vivo of the EC-modified LDL
produced in culture.
Anion exchange resin binds negatively charged 
proteins, which include LDL.. The affinity of binding 
depends on the magnitude of the negative charge on the 
protein and the concentration of counter ions in the 
surrounding buffer.
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Anion exchange column chromatography was 
employed to determine if there was a species of LDL, 
which had a higher negative charge than control LDL, in 
the plasma of RE suppressed animals.
The technique demonstrated that this was 
indeed the case. LDL from animals treated with MDP-Ac- 
BSA contained two separate fractions. One had the same 
net negative charge as control LDL and the second bound 
more strongly to the column, indicating a greater net 
negative charge.
PE-LDL eluted as a single peak but this also 
bound more strongly to the column than control LDL. 
There was, however, no distinct peak at the point where 
control LDL normally eluted.
So, LDL from animals treated with RE-system 
suppressants contains a species which has an increased 
net negative charge compared to control LDL. The 
presence of two peaks in MDP-treated rabbit LDL may be 
explained by the length of time the animal's RE-system 
was suppressed. Rabbits received a single dose of 
MDP-Ac-BSA and the LDL prepared from their plasma 24 
hours later. The process of conversion of LDL operated 
in these animals for only that length of time. In 
animals treated with ethyl oleate the RE-system was 
suppressed for a period of 5 days in all. The 
alterations occurring in LDL may have proceeded to a much 
greater extent in that case.
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Another factor may contribute to the 
difference between the LDL produced by ethyl oleate and by 
MDP-Ac-BSA suppression. As was stated above (section 
7.2.1), the profiles of tissue uptake of emulsions and 
acetylated proteins are different. This may be due to 
uptake of the latter by liver, endothelial cells (159) and 
may have an effect on the alteration of LDL.
LDL from ethyl oleate.treated animals was 
separated into two fractions by density gradient ultra­
centrifugation. The first of these had a near normal 
hydrated density but the second was significantly denser 
than control LDL (Fig.R34). Individual peaks were not 
analysed for electrophoretic mobility or cholesterol/ 
protein ratio. It is unclear why PE-LDL could be 
separated into two species by density but not by charge.
Analysis of total PE-LDL (containing both 
density fractions) showed a slight but significant 
increase in cholesterol/protein ratio which is 
inconsistent with the decrease observed in endothelial 
cell modified LDL. Attempts to detect oxidation products 
and free radicals in PE-LDL were inconclusive.
Nevertheless it appeared that RE-system 
suppression produced at least one new species of LDL 
which had increased density and increased net negative 
charge compared to control LDL. Interpretation of these 
results, at the simplest level, would seem to indicate 
that this species of LDL was normally catabolised rapidly 
by macrophages. This would mean that it was present in
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normal plasma and, indeed, in plasma from LDL-receptor 
deficient subjects at low concentrations. The conversion 
and rapid uptake of LDL by macrophages may be a naturally 
occurring "ageing" process which plays a significant role 
in the scavenger catabolism of LDL.
7.4; Metabolic Fate of LDL Produced During
RE-System Suppression
Fractional catabolic rates (FCRs) were calculated (120) 
for the clearance of LDL and PE-LDL from the plasma of 
normal rabbits. The FCR of PE-LDL was significantly 
greater than that for control LDL (p<0.001; Table R 5 ). 
As discussed in section 7.1, EC-modified LDL is rapidly 
catabolised via the Ac-LDL receptor on macrophages (142).
In the present study it was shown that PE-LDL was 
catabolised by tissues rich in RE-system macrophages, 
namely the liver, the spleen and the adrenal glands. The 
liver appears to be the most active tissue as far as the 
RE-system is concerned. It is said to catabolise the 
majority of blood borne substrates of the RE-system 
(131). This is consistent with the tissue uptake of 
PE-LDL; if PE-LDL is catabolised via the Ac-LDL receptor 
then the tissue which is richest in macrophage activity 
would degrade a major portion of that LDL. It is 
probable therefore, that the species of LDL produced on 
treatment with ethyl oleate is catabolised by macro­
phages.
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Further studies indicated that the altered 
species of LDL was formed in the circulation rather than 
being synthesised de novo. Control. LDL reisolated from 
ethyl oleate treated rabbits had increased electro­
phoretic mobility compared to control LDL reisolated from 
control rabbits. It was also cleared from the plasma at 
a greater rate when injected into normal animals. When 
control LDL and PE-LDL were reisolated from normal 
rabbits both had the same electrophoretic mobility and 
plasma clearance rates. This suggests that PE-LDL 
contains at least two species, one of which decays 
rapidly from the plasma where the other is removed at the 
same rate as control LDL. Presumably the rapidly cleared 
LDL has the larger overall negative charge. The two 
species model is further supported by examination of the 
terminal monoexponential portion of the decay curve for 
LDL preincubated in an ethyl oleate treated rabbit. This 
monoexponential decay closely resembles the decay of 
control LDL. According to Figure R35 the curve becomes 
monoexponential approximately 12 hours after injection at 
which time 80% of the tracer has been removed. It is 
interesting to note that more than 75% of total PE-LDL is 
present as the higher density form (Fig.R34). These data 
are consistent with earlier findings, and the simple 
model proposed above (section 7.3).
In vitro PE-LDL competes effectively for the 
acetyl-LDL receptor on macrophages, reducing degradation 
of Ac-LDL to less than 20% of that in the absence of
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competitor. This was not achieved with control rabbit 
LDL or human LDL at the same concentrations (Fig.R40). 
It has been shown that EC-modified LDL also competes 
effectively for the Ac-LDL receptor (142). It seems 
likely that PE-LDL is catabolised via this route in vivo. 
This evidence lends more weight to the two species model, 
and the proposal that PE-LDL is produced naturally in 
vivo then degraded rapidly by the RE-system.
7.5: LDL from RE-System Suppressed Animals and its
Role in Atherosclerosis
As has been discussed, the foam cells present in 
atherosclerotic plaques are partly derived from macro­
phages (11,17). Macrophages do not catabolise large 
enough quantities of normal lipoproteins to explain the 
gross amounts of lipid found in foam cells (139). 
Various explanations for the accumulation of lipid in 
macrophages have been given (section 7.1).
The ability of lipoproteins from RE 
suppressed animals to form foam cells and promote 
atherosclerosis was tested in vivo.
Under normal conditions rabbits have low 
levels of plasma lipoproteins (40) and do not develop 
atherosclerosis. However, if the animals are fed a diet 
containing cholesterol (1% w/w) their plasma cholesterol 
concentration increases rapidly (21,24). In 30-40 days 
it may reach 55-60 mmol/1. After 12 weeks on this
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regimen the animals develop significant numbers of 
atheromatous deposits in their aortae (24).
During the first 35-40 days, the influx of 
cholesterol into the aortae is steady but fairly slow 
(21). Thereafter an increasingly rapid deposition of 
cholesterol occurs leading to severe lesion formation 
over most of the intimai surface (21).
The effect of ethyl oleate treatment on the 
formation of atherosclerosis in rabbits was determined 
using cholesterol feeding to enhance atherogenesis. The 
animals were fed a cholesterol supplemented diet and half 
were injected with ethyl oleate twice weekly. There was 
no significant difference between the plasma cholesterol 
levels in treated and untreated rabbits at any time 
during the 40 days. The same was true for plasma 
triglyceride concentration. Forty days was chosen 
because, for the reasons given above, lesion formation is 
moderate in rabbit aortae after this period and would not 
obscure the possible effects had by ethyl oleate on the 
atherosclerotic process.
Fractional catabolic rates (FCRs) were 
calculated for LDL and met-LDL (as a marker of RE-system 
degradation) in both groups. There was no significant 
difference in the FCR of LDL and met-LDL in either of the 
groups. The tracers were also cleared at the same rate 
in both groups. Thus cholesterol feeding appeared to 
mask any effect ethyl oleate had on either cholesterol
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and triglyceride concentrations or on the clearance of 
LDL and met-LDL from the plasma.
Examination of the aortae of the animals 
revealed that treatment with ethyl oleate significantly 
increased the preponderance of atherosclerosis (Table R8, 
Fig.R48). Agarose gel electrophoresis showed that LDL 
from treated rabbits had a higher electrophoretic 
mobility than that from untreated animals.
It would appear, therefore, that suppression 
of the RE-system and hence macrophages caused a build up 
of more negatively charged LDL which had a greater 
capacity for atherogenesis. This would seem to be in 
contradiction to the mechanism discussed previously 
(sections 7.1 and 7.2).
The rabbits were injected with a macrophage 
inhibiting agent which reduces^ degradation of altered 
LDL. This would, at first, be expected to apply to 
histiocytes, preventing them from becoming foam cells. 
However, the liver and spleen are responsible for the 
uptake of more than 95% of the targeted drugs. The 
percentage taken up by the aorta was too small to be 
measured in these terms. It is possible that ethyl 
oleate vesicles were removed by the liver and spleen at a 
rate which did not allow for suppression of tissue 
macrophages.
A l t h o u g h  there is a slight reduction in the 
number of blood borne monocytes, there is no evidence 
that these cells are o t h e r w i s e  a f f e c t e d  by R E - s y s t e m
?•
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suppressants. Injections of ethyl oleate were given at 
3-4 day intervals and cleared from the plasma in a matter 
of minutes. It is, therefore, possible that monocytes, 
and hence histiocytes, which are affected by the 
suppressants, are few in number. This would mean that 
normally functioning macrophages were present in the 
intima with acetyl-LDL receptors available for the uptake 
of altered LDL (which would be present in the plasma in 
increased amounts under these circumstances).
7.6; Conclusions
Su p p r e s s  ion ' o::0 /'-t'h'e R É ^sÿ associated with an
increase in thë plasma concent of an altered form of
‘ L D L . This altered LDL has an increased density, an 
inc r e a s e d  e l e c t r o p h o r e t i c  m o b i l i t y  and ,an. •ihc'reaèed 
c h q l e s t e r g l  to protein r a t i o %  rempved rapidly from 
the p l a s m a  of control animals .probably via t h e ,Ac-LDL 
receptor,/ since it competes for-that receptor in vitro^
Various mechanisms have been proposed for the 
formation of altered LDL in vivo. Most realistic of 
these, in light of the amount and characteristics of LDL 
produced, would seem to be retroendocytosis. However, 
other mechanisms may play a role in atherosclerosis. 
These include chemical modification by agents released on 
the aggregation of platelets, complexes formed with 
polyanionic macromolecules present in the intima, 
oxidation of LDL by superoxide ions or free radicals and
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insudation of altered LDL into the intima from the plasma 
(Fig.Dl).
It would seem that because circulating 
altered LDL is catabolised very rapidly it would have 
little relevance to the atherosclerotic process and only 
the conversions taking place in and around a plaque could 
contribute to foam cell formation. However, in 
individuals with high plasma levels of LDL, the amount of 
altered LDL being produced in the circulation may 
increase. There is no evidence available to support this 
in familial hypercholesterolaemics but little work has 
been done in these individuals to determine whether 
altered LDL is present and, if so, in what quantities.
The main findings arising out of this study are:-
a) Suppressive drugs can be successfully targeted to the
Reticuloendothelial system, specifically to the 
macrophages thereof.
b) Suppressive agents (such as ethyl oleate and MDP) 
elicit an increase in plasma cholesterol and 
triglyceride concentrations, though not necessarily 
by the same mechanism.
c) The rise in plasma cholesterol is caused mainly by an
increase in LDL cholesterol, suggesting that a
mechanism for the catabolism of that lipoprotein is
inhibited. This mechanism appears to be the LDL- 
receptor independent pathway.
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- converted LDL capable of interaction with the ac-LDL receptor
- conversion of LDL within endothelial cells
- retroendocytosis
- uptake of altered LDL via the ac-LDL receptor
- interaction of LDL with polyanionic substances in the intima
- reaction of LDL with chemical agents released on the 
aggregation of platelets
- stimulation of smooth muscle cell proliferation by macrophage 
derived growth factor
- macrophage derived growth factor increases the number of LDL 
receptors (U) on smooth muscle cells
- increased uptake of LDL by smooth muscle cells
- macrophage derived growth factor stimulated the migration of 
smooth muscle cells from the media into the intima
- oxidation of LDL by superoxide ion or free radicals
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d) The LDL which accumulated in vivo had an increased 
density and an increased net negative charge. It was 
an effective competitor for macrophage degradation of 
acetyl-LDL.
e) Altered LDL was cleared from the plasma of normal 
rabbits with an FCR almost 2 fold greater than that 
for control LDL. This species was formed in the 
circulation rather than being synthesised de novo.
f) Treatment with ethyl oleate significantly increased 
the amount of atherosclerosis found in the aortae of 
rabbits fed a diet supplemented with cholesterol for 
40 days.
The formation of altered LDL in the plasma may be a
naturally occuring "ageing" process which aids in the
overall catabolism of the lipoprotein. However, it does
not account for all the LDL degraded by the RE-system.
Individuals with myeloproliferative disorders have
significantly higher fractional clearance rates for LDL
( 99 , 1 00 , 1 74 ). There is no physiological or biochemical
reason why these subjects should produce more altered
r
LDL, therefore, it must be sussed that the RE-system 
degrades LDL by more than one mechanism.
S i g n i f i c a n t  amounts of LDL do, however, 
accumulate in the plasma of RE-system suppressed animals 
so it w o uld a ppear that this m e c h a n i s m  does play an 
important role in the LDL-receptor independent pathway.
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Some questions remain unanswered here, and 
more have been raised. Perhaps foremost among these 
concerns the mechanism by which LDL. is altered in vivo. 
Some proposals have been made, mainly involving the 
phenomenon of retroendocytosis. There are some 
similarities between the accumulated LDL and that 
obtained on incubation with cultured endothelial cells 
(142,147) but they are not identical.
Treatment of cholesterol fed animals with 
ethyl oleate produces a greater preponderance of athero­
sclerosis but it is not known if RE suppression alone can 
induce atherosclerosis.
The physical and chemical properties of 
altered LDL are not fully documented. Effects on the 
lipids and apoproteins of . LDL require further
investigation.
In this study low density lipoproteins have 
been investigated but, apart from plasma concentrations, 
the effect of RE suppression on other lipoprotein classes 
has not been considered.
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